

Self-rated Health and Type 2 Diabetes Risk in the EPIC-InterAct Study: a case-cohort study

Journal:	BMJ Open
Manuscript ID:	bmjopen-2012-002436
· · · · · · · · · · · · · · · · · · ·	bmjopen-2012-002436
Article Type:	Research
Date Submitted by the Author:	03-Dec-2012
Complete List of Authors:	Wennberg, Patrik; Umeå University, Public Health and Clinical Medicine, Family Medicine Rolandsson, Olov; Umeå University, Public Health and Clinical Medicine, Family Medicine van der A, Daphne; National Institute for Public Health and the Environment, Centre for Prevention and Health Services Research Spijkerman, Annemieke; National Institute for Public Health and the Environment, Centre for Prevention and Health Services Research Kaaks, Rudolf; German Cancer Research, CenterDivision of Cancer Epidemiology Boeing, Heiner; German Institute of Human Nutrition Potsdam-Rehbrücke, Department of Epidemiology Feller, Silke; German Institute of Human Nutrition Potsdam-Rehbrücke, Department of Epidemiology Bergmann, Manuela; German Institute of Human Nutrition Potsdam-Rehbrücke, Department of Epidemiology Langenberg, Claudia; Institute of Metabolic Science, Addenbrooke's Hospital,, MRC Epidemiology Unit Sharp, Stephen; University of Cambridge, ; Institute of Metabolic Science, Addenbrooke's Hospital, MRC Epidemiology Unit Forouhi, Nita; MRC Epidemiology Unit, Riboli, Elio; Imperial College London, Department of Epidemiology & Biostatistics, School of Public Health Wareham, Nicholas; University of Cambridge, Institute of Public Health
Primary Subject Heading :	Diabetes and endocrinology
Secondary Subject Heading:	Public health
Keywords:	DIABETES & ENDOCRINOLOGY, General diabetes < DIABETES & ENDOCRINOLOGY, PREVENTIVE MEDICINE

SCHOLARONE[™] Manuscripts

Self-rated Health and Type 2 Diabetes Risk in the EPIC-InterAct Study: a

case-cohort study

P. Wennberg 1; O. Rolandsson 1; D.L. van der A 2; A.W. Spijkerman 2; R. Kaaks 3; H. Boeing 4; S. Feller 4; M.M. Bergmann 4; C. Langenberg 5; S.J. Sharp 5; N. Forouhi 5; E. Riboli 6; N. Wareham 5

1. Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden; 2. National Institute for Public Health and the Environment, Centre for Prevention and Health Services Research, Bilthoven, The Netherlands; 3. Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 4. Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbrücke, Nuthetal, Germany; 5. MRC Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, United Kingdom; 6. Department of Epidemiology & Biostatistics, School of Public Health, Imperial College London, London, United Kingdom.

Correspondence: P. Wennberg

Address: Portstigen 24, 931 51 Skellefteå, Sweden

Fax: +46 90 776883, Telephone: +46 90 7851423

E-mail: patrik.wennberg@fammed.umu.se

Key words: Type 2 diabetes, self-rated health, prevention, case-cohort

Word count (main text): 3426

Word count (abstract): 247

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if accepted) to be published in BMJ Open and any other BMJPGL , a , pdf.) and the Ck. , y made under these tek products to exploit all subsidiary rights, as set out in our licence (http://group.bmj.com/products/journals/instructions-forauthors/wholly owned licence.pdf) and the Corresponding Author accepts and understands that any supply made under these terms is made by BMJPGL to the

Corresponding Author.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Abstract

Objectives To investigate the association between self-rated health and risk of type 2 diabetes.

Design Population-based prospective case-cohort study.

Setting Enrolment took place between 1992 and 2000 in five European centres (Bilthoven, Cambridge, Heidelberg, Potsdam, Umeå).

Participants Self-rated health was assessed by baseline questionnaire in 3,399 incident type 2 diabetic case participants and a centre-stratified subcohort of 4,619 individuals from the EPIC-InterAct study which was drawn from a total cohort of 340,234 participants in the European Prospective Investigation into Cancer and Nutrition (EPIC).

Primary outcome measure Prentice-weighted Cox regression was used to estimate centre-specific hazard ratios (HRs) and 95% confidence intervals (CIs) for incident type 2 diabetes controlling for age, sex, centre, education, BMI, smoking, alcohol consumption, energy intake, physical activity, and hypertension. The centre-specific HRs were pooled across centres by random effects meta-analysis.

Results Low self-rated health was associated with a higher hazard of type 2 diabetes after adjusting for age and sex (pooled HR 1.67, 95% CI 1.48 to 1.88). After additional adjustment for health-related variables including BMI, the association was attenuated but remained statistically significant (pooled HR 1.29, 95% CI 1.09 to 1.53). I² index for heterogeneity across centres was 13.3% (p=0.33).

Conclusions Low self-rated health was associated with a higher risk of type 2 diabetes. The association could be only partly explained by other health-related variables, of which obesity was the strongest. We found no indication of heterogeneity in the association between self-rated health and type 2 diabetes mellitus across the European centres.

Article Summary

Article focus

- Self-rated health has been widely used as a global health measure. Several cross-sectional studies have suggested an association between low self-rated health and type 2 diabetes mellitus.
- We aimed to prospectively investigate the association between self-rated health and risk of type 2 diabetes. A population-based case-cohort study design was used and five European centers were included in the study.

Key messages

- Results from this study provide some evidence that low self-rated health is associated with a higher risk of type 2 diabetes mellitus. The association could be only partly explained by other health-related variables, of which obesity was the strongest.
- We found no indication of heterogeneity in the association between self-rated health and type 2 diabetes mellitus across centres.

Strength and limitations

- The study used a thorough ascertainment and verification of type 2 diabetes mellitus cases and included populations from four different European countries.
- The assessment of self-rated health differed somewhat between centres regarding time frames for the self-rated health question.

Introduction

The prevalence of type 2 diabetes mellitus (T2DM) worldwide has more than doubled since 1980.¹ In 2010, it was estimated that over 250 million people suffered from T2DM.² Several risk factors have been identified (e.g. age, BMI, family history and physical inactivity) but the aetiology of T2DM is complex and still largely unknown. Selfrated health (SRH) is a subjective measure of health usually defined by responses to a single question such as "How do you rate your health?". SRH is suggested to capture physical, psychological and social aspects that may be difficult to assess by objective health measurements³. Furthermore, SRH has been associated with bodily sensations and symptoms that can reflect disease in clinical or pre-clinical stages.⁴⁻⁵ Individuals with poor self-rated health (SRH) tend to have higher mortality,^{3 6} poorer physical activity⁷ and higher health care utilization⁸ than individuals rating their health as excellent or good. Several cross-sectional studies in different populations have reported associations between poor SRH and prevalent diabetes⁹⁻¹¹ or glucometabolic disturbance.¹² To our knowledge, only one previous prospective study on the association between SRH and incidence of T2DM has been published, showing that reduced SRH is associated with newly diagnosed T2DM after a five year follow-up.¹³ However, this prospective study was limited by high loss to follow-up. The EPIC-InterAct Study is a large case-cohort study that provides an ideal setting to investigate the association between SRH and T2DM across several European countries.

Methods

Study population

The InterAct Project was initiated to investigate how genetic and lifestyle behavioural factors, particularly diet and physical activity, interact on the risk of developing diabetes and how knowledge about such interactions may be translated into preventive action. The EPIC-InterAct case-cohort study was nested in the European Prospective

Investigation into Cancer and Nutrition (EPIC), which in total consists of 519,978 men and women across Europe.¹⁴ Out of these, 340,234 participants were eligible for the EPIC-InterAct study, which includes centres from eight different European countries (Denmark, France, Germany, Italy, the Netherlands, Spain, Sweden and the United Kingdom). A detailed description of the study design and methods can be found elsewhere.¹⁵ In the present analysis we only included centres that had baseline data available on self-rated health (Germany: Heidelberg and Potsdam; the U.K.: Cambridge; the Netherlands: Bilthoven; Sweden: Umeå). Participants were 25 to 70 years old at enrolment between 1992 and 2000. Among the participants from the five centres included in this study, 3,412 incident T2DM cases were identified and a subcohort of 4,637 individuals were randomly selected after exclusions for prevalent diabetes or unknown diabetes status. Data on self-rated health was available for 4,619 individuals in the subcohort and 3,399 incident T2DM cases. Due to the random nature of the casecohort design applied in the present study, the subcohort also included 140 individuals who developed T2DM during follow-up. All participants gave written consent and the study was approved by the ethical review board of the International Agency for Research on Cancer and by the local review boards of the participating centres.

Ascertainment of T2DM cases

Incident cases of T2DM until 31 December 2007 were ascertained and verified at each EPIC centre participating in the Epic-Interact project using follow-up questionnaires (T2DM diagnosed by a medical doctor or anti-diabetic drug use), linkage to primary and secondary care registers, medication use (prescription registers), hospital admission and mortality data. Cases in Sweden were not ascertained by self-report, but identified via local and national diabetes and pharmaceutical registers and hence all ascertained cases were considered to be verified.¹⁵ To increase the specificity of the case definition and to avoid inclusion in the study based on self-report of T2DM alone, further evidence was sought for all incident cases of T2DM. T2DM cases were included in the study only if

BMJ Open

confirmation of the diagnosis was secured from no less than two independent sources, including individual medical-record review.

Assessment of self-rated health

SRH was assessed at baseline using self-administered questionnaires in the native language. The questionnaires were somewhat differently formulated at each centre and were therefore standardized (described in **Appendix**). Given the low frequency of responses in the extreme categories (n=305 in the lowest category) we dichotomized the SRH variable in the analysis by combining the two highest categories (high SRH) and the two lowest categories (low SRH) in conformity with previous research.¹⁶⁻¹⁸

Assessment of covariates

Weight and height were measured with participants not wearing shoes. Each participant's body weight was corrected for clothing worn during measurement in order to reduce heterogeneity due to protocol differences among centres.¹⁹ Body mass index (BMI) was calculated, as weight (kilograms) divided by height (metres) squared. Hypertension was defined as self-reported medical history of hypertension or hypertension (based on measurements or drug use) at baseline. Further health-related variables were collected using questionnaires including questions on educational level, smoking status (current smoker versus non-smoker or ex-smoker), diet, physical activity level, alcohol consumption, and previous myocardial infarction. Physical activity (PA) was assessed using the Cambridge index, a validated ordered categorical global index of activity derived from simple questions assessing recreational and occupational activity.²⁰

Statistical analysis

The association between SRH and various baseline characteristics within the subcohort was tested using a chi-square test (for categorical variables) and a Kruskal-Wallis test (for continuous variables). Cox proportional hazards regression, modified for the case-cohort design according to the Prentice method,²¹ was used to estimate centre-specific

hazard ratios (HRs) and 95% confidence intervals (CI) for the association between SRH and T2DM. Age was used as the primary time variable, with entry time defined as the participant's age in years at recruitment and exit time as the participant's age in years at date of diagnosis, death or censoring. The centre-specific HRs were then pooled across centres by random effects meta-analysis.

It is not clear whether SRH mechanistically operates as an indicator of some unmeasured process or as a summary of a large number of other measures.^{3 22} Therefore, a large set of covariates were considered as potential confounders and included in models to determine pooled HRs at different levels of adjustment. All models were adjusted for age and sex. Each model was then further adjusted for the other health-related variables, one at a time and finally, all potential confounders in the same model. Education level, smoking status, physical activity and hypertension were included as categorical variables, whereas BMI, alcohol consumption and energy intake were included as continuous variables. I^2 – the percentage of variation between centres due to heterogeneity – was calculated. A possible interaction between SRH and sex on T2DM incidence was tested by introducing an interaction term in the regression analysis. We conducted a sensitivity analysis by excluding participants who were diagnosed with T2DM within two years of follow-up. In a second sensitivity analysis we excluded all participants with history of myocardial infarction at baseline. To investigate the impact of missing data, a third sensitivity analysis was conducted by multiple imputation of missing data considered missing at random (based on 5, 10 and 50 imputations) in cases and non-cases. For each variable with missing data, a predictive model was created among participants with no missing data; that model was then used to predict values for participants who were missing those data.²³ All analyses were performed using Stata 11.2, except for the random effects meta-analysis which was performed using Comprehensive Meta-Analysis version 2.

Results

The mean follow-up time was 9.1 years (\pm 3.8). SRH by centre in incident cases of T2DM and subcohort individuals is presented in **Table 1. Table 2** shows the baseline characteristics of individuals in the subcohort by categories of SRH. Participants with low SRH were younger, had lower educational level and a higher BMI than participants with high SRH. Moreover, participants with low SRH were more often smokers, less physically active, had lower alcohol consumption and estimated reported energy intake, and more frequently had hypertension and a history of myocardial infarction than persons with high SRH.

In a model with adjustment for age and centre, low SRH was associated with a higher hazard of T2DM (HR 1.67, 95% CI 1.48 to 1.88) (**Table 3**). We found no significant interaction between SRH and sex on T2DM incidence (p=0.54) and the analyses were therefore not stratified by sex. The strength of the association between SRH and T2DM was mainly unaffected by adjustment for smoking, alcohol consumption and estimated reported energy intake. Adjustment for other health-related variables, BMI in particular, led to attenuation of the association (adding BMI to the model attenuated the pooled HR to 1.38, 95% CI 1.19 to 1.60). In a final model with adjustment for age, sex, education, BMI, smoking, physical activity, alcohol consumption, estimated reported energy intake and hypertension, the association was attenuated but remained significant (HR 1.29, 95% CI 1.09 to 1.53). The centre-specific HRs and the pooled HR based on the final model are presented in **Figure 1**. We found no indication of heterogeneity in the association between SRH and T2DM across centres (I² index 13.3%, p=0.33).

In a first sensitivity analysis we excluded participants who were diagnosed with T2DM within two years of follow-up (n=398). These exclusions had only minor effect on the pooled HR (1.29, 95% CI 1.08 to 1.55, adjusted for the variables in the final model). The number of participants with history of myocardial infarction was low (n=202) and the multivariate model did not fit when this covariate was included. Thus, in the second sensitivity analysis we excluded all participants with a history of myocardial infarction at

baseline. This did not change the conclusions (pooled HR 1.27, 95% CI 1.08 to 1.50, adjusted for the variables in the final model). Because of missing data on covariates, 323 T2DM cases and 405 members of the subcohort were excluded from analyses. As a third sensitivity analysis, multiple imputations of these data, assuming missingness at random, were conducted. No significant differences in results were found in datasets based on 5, 10 or 50 imputations, compared to the original dataset. Therefore, it seems unlikely that the results are biased due to missing data.

Discussion

In this prospective case-cohort study we found that low SRH was associated with a higher risk of T2DM. The association was partly explained by other health-related variables, particularly BMI. We found no indication of heterogeneity in the association between SRH and T2DM across the European centres.

SRH has been widely used as a global health measure. Previous studies on general populations have shown that there is a strong relationship between SRH and mortality, even after controlling for sociodemographic factors, objective measures of health status, and health behaviours ^{6 24}. A few studies have investigated the association between SRH and mortality in populations of diabetes patients with results similar to those of general populations ^{17 25-26}. SRH and prevalent diabetes have been associated in several cross-sectional studies ^{9-12 27}. However, cross-sectional studies are limited by their inability to study the temporal sequence of exposure and disease. Furthermore, these studies have not separated type 2 and type 1 diabetes.

Any causality cannot be established by an observational study, but the findings in this prospective study imply that there is a dominant direction of this association from low SRH to T2DM (i.e. a temporal relationship). We have only found one previous prospective study of the association between SRH and T2DM in a large general population. In the Australian Diabetes Obesity and Lifestyle study, Tapp et al. ¹³ found that participants with newly diagnosed diabetes had reported impaired general health

BMJ Open

before the onset of T2DM. The study was limited by a shorter follow-up (5 years) and they did not present any sensitivity analysis with exclusion of participants, who were diagnosed with T2DM shortly after baseline, which makes a bidirectional association more likely. Furthermore, the study was limited by a low follow-up response rate.

In the present study, low SRH was associated with a higher BMI which is in line with previous research. In a study investigating the relationship between self-rated health and obesity, Prosper et al. found that obese individuals had a 3-fold greater odds of reporting reduced health compared to individuals with normal weight or overweight. As obesity is also considered to be a major risk factor for diabetes ²⁸, obesity is likely to explain a substantial part of the association between low SRH and T2DM. Thus, it is not surprising that BMI may act as an important confounder in the association between SRH and T2DM in this study -or as a mediator since SRH and obesity might be on the same causal pathway.

Previous research on occupational cohorts has suggested that SRH principally reflects physical and mental health problems and to a lesser extent age, early life factors, family history, sociodemographic variables, psychosocial factors, and health behaviours ²². One study that used in-depth interviews found that the same frame of reference is not used by all respondents in answering this question ²⁹. Some study participants think about specific health problems when asked to rate their health, whereas others think in terms of either general physical functioning or health behaviours. In our study, the question for SRH referred to different time frames (e.g. perception of health *today* in Germany and perception of health over the *last year* in Sweden). SRH has shown to be stable over time in population-based studies, suggesting that a considerable component of SRH reflects an aspect of one's enduring self-concept and to a lesser extent a spontaneous assessment of one's health status ³⁰. Thus, the impact of different time frames on SRH assessment is likely to be small.

Compared to studies of SRH with mortality outcomes in individuals with diabetes ^{17 25-26} the strength of the SRH association (with T2DM incidence) found in the present study

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

was weak. There may be several explanations for this. It has been shown that diabetes patients have higher mortality rates from several causes ³¹, including cancer ³². It is likely that the comparatively strong association between SRH and mortality is due to a higher ability for SRH to summarize global health risk among diabetes patients than specifically metabolic risk in a general population. It is also possible that SRH is more susceptible to "reporting behaviour" (i.e. how optimistic or pessimistic people are about their health) ³³ in a generally healthier population compared to subjective health ratings later on in the disease process.

Previous findings suggest that there may be sex differences in the SRH-mortality association ³⁴ but we found no sex difference in the association between SRH and T2DM. SRH may also vary across countries ³⁵. In the present study, it is likely that the differences in SRH across centres to some extent can be explained by different sampling strategies and age distributions at different centres. We did not find support for heterogeneity in the association between SRH and T2DM across centres in this study. However, the study was restricted to countries in northern Europe. It is therefore not clear how these findings are generalisable to other populations.

Strengths of the present study include the thorough ascertainment and verification of T2DM cases. Moreover, cultural differences may also have an impact on SRH, even within Europe and we included populations from four different European countries ³⁶. Several limitations of the study have already been listed, such as different time frames for the SRH question and the restriction to countries in northern Europe. We would also like to point out that it is possible that participants reporting low SRH at baseline were more likely to seek medical advice during follow-up and hence were more likely to be tested for diabetes (detection bias). If this was the case, the study may have overestimated the risk of T2DM associated with low SRH.

In our study, part of the SRH-T2DM association seemed to be explained by medical history as well as lifestyle variables. SRH may therefore be considered as a summary health measure – also for metabolic health. If there is access to several of the

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

established risk factors for diabetes, self-rated health is not likely to add more than marginally to risk prediction on top of the conventional risk factors. However, whether SRH adds predictive value over and above established risk factors needs to be further analysed using adequate methods ³⁷.

In conclusion, results from this prospective case-cohort study provide some evidence that low self-rated health is associated with a higher risk of type 2 diabetes mellitus. The association could be only partly explained by other health-related variables, of which obesity was the strongest.

Footnotes

Contributors: PW had access to all data for this study, analysed the data, drafted the manuscript and is the guarantor. All authors qualify for authorship according to BMJ Open criteria. They have all contributed to conception and design, and interpretation of data, revising the article critically for important intellectual content and final approval of the version to be published.

Competing interests: All authors have completed the Unified Competing Interest form at <u>www.icmje.org/coi disclosure.pdf</u> (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisation that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Funding: Funding for the InterAct project was provided by the EU FP6 programme [grant number Integrated Project LSHM_CT_2006_037197]. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. In addition, InterAct investigators acknowledge funding from the following agencies: DLvdA and AMWS: Dutch Ministry of Public Health, Welfare and Sports (VWS),

Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); RK: Deutsche Krebshilfe.

Ethical approval: The study was approved by the IARC Institutional Review Board and by the local review boards of the participating centres.

Data sharing: No additional data available.

<text><text>

BMJ Open

Table 1 Self-rated health by centre in 3,399 incident cases of type 2 diabetes mellitus and 4,619 participants in the subcohort in the EPIC-InterAct study. Data shown are numbers of individuals (percentage).

			Self-rate	d health		
Centre		Hi	gh	Low		
		Excellent	Good	Moderate	Poor	
Bilthoven	Cases	13 (4.3)	184 (61.5)	73 (24.4)	29 (9.7)	
	Subcohort	52 (9.0)	403 (70.0)	101 (17.5)	21 (3.6)	
Cambridge	Cases	92 (12.3)	428 (57.1)	206 (27.5)	24 (3.2)	
	Subcohort	159 (16.2)	624 (63.4)	170 (17.4)	23 (2.3)	
Heidelberg	Cases	173 (23.1)	395 (52.8)	156 (20.9)	24 (3.2)	
	Subcohort	286 (32.9)	448 (51.5)	125 (14.4)	11 (1.3)	
Potsdam	Cases	118 (15.2)	460 (59.4)	171 (22.1)	26 (3.4)	
	Subcohort	274 (23.1)	721 (60.9)	164 (13.9)	25 (2.1)	
Jmeå	Cases	155 (18.7)	369 (44.6)	236 (28.5)	67 (8.1)	
	Subcohort	265 (26.2)	477 (47.1)	215 (21.2)	55 (5.4)	

Table 2 Baseline characteristics of subcohort individuals in the EPIC-InterAct study by categories of self-rated health. Data are presented as mean and standard deviations (SD) for continuous variables and percentages and frequencies for categorical variables.

				Self-rate	ed health				
	High			Low					
	Excel	ent	Goo	Good		Moderate		Poor	
	Mean/%	SD/N	Mean/%	SD/N	Mean/%	SD/N	Mean/%	SD/N	overall difference [*]
Age (years)	48.8	10.3	50.5	11.1	51.7	10.9	50.3	10.2	<0.001
Sex (% men)	42.8	443	45.2	1208	44.8	347	37.8	51	0.24
Educational level (%)									<0.001
Primary school or none	19.2	194	24.4	635	37.9	287	30.8	40	
Technical/ professional school	34.6	351	35.0	910	29.6	224	32.3	42	
Secondary school	14.9	151	14.2	369	14.4	109	18.5	24	
Higher (incl. university degree)	31.3	317	26.4	688	18.1	137	18.5	24	
BMI (kg/m²)	24.8	3.4	25.5	4.0	26.2	4.5	25.6	5.4	<0.001
Smoking status (%)									< 0.001
Never	52.1	540	46.6	1246	41.7	323	40.7	55	
Former	27.5	285	30.1	804	30.1	233	23.7	32	
Current	18.8	195	21.0	561	26.1	202	32.6	44	
Unknown	1.5	16	2.3	62	2.2	17	3.0	4	
Physical activity (%)									< 0.001
Inactive	15.9	160	21.3	548	31.1	231	43.3	52	
Moderately inactive	33.2	335	31.7	818	28.8	214	29.2	35	
Moderately active	25.5	257	26.8	689	21.8	162	15.0	18	
Active	25.5	257	20.2	521	18.2	135	12.5	15	
Alcohol consumption (g/d)	11.5	16.2	10.8	15.2	9.2	15.4	5.6	9.8	<0.001
Total energy intake (kcal)	2016.6	649.7	2056.7	618.3	2009.4	617.3	1928.3	617.9	0.007
Hypertension (%)	16.0	165	22.8	600	32.7	245	33.3	44	<0.001
History of myocardial infarction (%)	0.4	4	1.5	40	3.6	28	3.7	5	<0.001

*Comparing excellent, good, moderate, and poor self-rated health

 Table 3 Pooled hazard ratios of incident T2DM comparing low (moderate or poor) versus high (excellent or good) self-related health.

	High self-rated health	Low self-rated health
	Pooled HR (95% CI)	Pooled HR (95% CI)*
Model 1: Adjusted for age and sex	1.00 (referent)	1.67 (1.48 to 1.88)
Model 1 + education	1.00 (referent)	1.60 (1.42 to 1.81)
Model 1 + BMI	1.00 (referent)	1.38 (1.19 to 1.60)
Model 1 + smoking	1.00 (referent)	1.67 (1.48 to 1.89)
Model 1 + physical activity	1.00 (referent)	1.59 (1.41 to 1.80)
Model 1 + alcohol consumption	1.00 (referent)	1.67 (1.48 to 1.89)
Model 1 + energy intake	1.00 (referent)	1.67 (1.48 to 1.88)
Model 1 + hypertension	1.00 (referent)	1.48 (1.31 to 1.69)
Model 1 + all covariates above	1.00 (referent)	1.29 (1.09 to 1.53)

*Pooled hazard ratios calculated using a centre-stratified approach in combination with a random effects meta-analysis.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Centre	Statistics for each study				н	azard r	atio a	nd 95%	6 CI		
	Hazard ratio	Lower limit	Upper limit	<i>p</i> -value							
Bilthoven	1.87	1.13	3.09	0.015				-		-	
Cambridge	1.34	0.95	1.89	0.092				_ ∎	∎─┤		
Heidelberg	1.37	0.96	1.97	0.083					◼─┤		
Potsdam	1.32	0.96	1.81	0.085				∎	┣─│		
Umeå	1.03	0.77	1.37	0.852					•		
Pooled	1.29	1.09	1.53	0.003				<	>		
					0.1	0.2	0.5	1	2	5	10

p-value for heterogeneity 0.33, I^2 index 13.3%

Figure 1 Centre-specific and pooled hazard ratios of incident T2DM adjusted for the variables in the final model (age, sex, education, BMI, smoking, physical activity, alcohol consumption, energy intake and hypertension).

FUNDING

Funded by EU FP6 programme

CONTRIBUTORSHIP

PW had access to all data for this study, analysed the data, drafted the manuscript and is the guarantor. All authors qualify for authorship according to BMJ Open criteria. They have all contributed to conception and design, and interpretation of data, revising the article critically for important intellectual content and final approval of the version to be published.

COMPETING INTERESTS

None

3 4 5

6 7 8

9 10

11

12

13

14

15

16 17

18

19

20

21

22

23

24

25

26

27

28

29 30

31

32

33

34

35

36

37

38

39

40

41 42

43

44

45

46

47

48

49

50

51

52

53

54

55 56

57

DATA SHARING

No additional data available.

References

- Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. National, regional, and 1. global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011;378(9785):31-40.
- 2. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87(1):4-14.
- 3. Idler EL, Benyamini Y. Self-rated health and mortality: a review of twenty-seven community studies. J. Health Soc. Behav. 1997;38(1):21-37.
- 4. Benyamini Y. Why does self-rated health predict mortality? An update on current knowledge and a research agenda for psychologists. *Psychol Health* 2011;26(11):1407-13.
- 5. Halford C, Anderzen I, Arnetz B. Endocrine measures of stress and self-rated health: a longitudinal study. J Psychosom Res 2003;55(4):317-20.
- 6. DeSalvo KB, Bloser N, Reynolds K, He J, Muntner P. Mortality prediction with a single general self-rated health question. A meta-analysis. J Gen Intern Med 2006;21(3):267-75.
- 7. Mavaddat N, Kinmonth AL, Sanderson S, Surtees P, Bingham S, Khaw KT. What determines Self-Rated Health (SRH)? A cross-sectional study of SF-36 health domains in the EPIC-Norfolk cohort. J Epidemiol Community Health 2011;65(9):800-6.
- 8. DeSalvo KB, Jones TM, Peabody J, McDonald J, Fihn S, Fan V, et al. Health care expenditure prediction with a single item, self-rated health measure. Med Care 2009;47(4):440-7.
- 9. Ramkumar A, Quah JL, Wong T, Yeo LS, Nieh CC, Shankar A, et al. Self-rated health, associated factors and diseases: a community-based cross-sectional study of Singaporean adults aged 40 years and above. Ann. Acad. Med. Singapore 2009;38(7):606-7.
- 10. Shadbolt B. Some correlates of self-rated health for Australian women. Am J Public Health 1997;87(6):951-6.
- 11. Manor O, Matthews S, Power C. Self-rated health and limiting longstanding illness: interrelationships with morbidity in early adulthood. Int J Epidemiol 2001;30(3):600-7.
- 12. Leosdottir M, Willenheimer R, Persson M, Nilsson PM. The association between glucometabolic disturbances, traditional cardiovascular risk factors and self-rated health by age and gender: a cross-sectional analysis within the Malmo Preventive Project. Cardiovasc *Diabetol* 2011;10:118.
- 13. Tapp RJ, O'Neil A, Shaw JE, Zimmet PZ, Oldenburg BF. Is there a link between components of health-related functioning and incident impaired glucose metabolism and type 2 diabetes? The Australian Diabetes Obesity and Lifestyle (AusDiab) study. Diabetes Care 2010;33(4):757-62.
- 14. Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 2002;5(6B):1113-24.
- 15. Langenberg C, Sharp S, Forouhi NG, Franks PW, Schulze MB, Kerrison N, et al. Design and cohort description of the InterAct Project: an examination of the interaction of genetic and lifestyle factors on the incidence of type 2 diabetes in the EPIC Study. Diabetologia 2011;54(9):2272-82.
- 16. Walker JD, Maxwell CJ, Hogan DB, Ebly EM. Does self-rated health predict survival in older persons with cognitive impairment? J. Am. Geriatr. Soc. 2004;52(11):1895-900.



	BMJ Open
17.	McEwen LN, Kim C, Haan MN, Ghosh D, Lantz PM, Thompson TJ, et al. Are health-related quality-of-life and self-rated health associated with mortality? Insights from Translating Research Into Action for Diabetes (TRIAD). <i>Prim Care Diabetes</i> 2009;3(1):37-42.
18.	Lee SJ, Moody-Ayers SY, Landefeld CS, Walter LC, Lindquist K, Segal MR, et al. The relationship between self-rated health and mortality in older black and white Americans. J. Am. Geriatr. Soc. 2007;55(10):1624-9.
19.	Pischon T, Boeing H, Hoffmann K, Bergmann M, Schulze MB, Overvad K, et al. General and abdominal adiposity and risk of death in Europe. <i>N Engl J Med</i> 2008;359(20):2105-20.
20.	Validity of a short questionnaire to assess physical activity in 10 European countries. <i>Eur J Epidemiol</i> 2012;27(1):15-25.
21.	Barlow WE, Ichikawa L, Rosner D, Izumi S. Analysis of case-cohort designs. <i>J Clin Epidemiol</i> 1999;52(12):1165-72.
22.	Singh-Manoux A, Martikainen P, Ferrie J, Zins M, Marmot M, Goldberg M. What does self rated health measure? Results from the British Whitehall II and French Gazel cohort studies. <i>J. Epidemiol. Community Health</i> 2006;60(4):364-72.
23.	Kenward MG, Carpenter J. Multiple imputation: current perspectives. <i>Stat. Methods Med. Res.</i> 2007;16(3):199-218.
24.	Benjamins MR, Hummer RA, Eberstein IW, Nam CB. Self-reported health and adult mortality risk: an analysis of cause-specific mortality. <i>Soc Sci Med</i> 2004;59(6):1297-306.
25.	Wennberg P, Rolandsson O, Jerden L, Boeing H, Sluik D, Kaaks R, et al. Self-rated health and mortality in individuals with diabetes mellitus: prospective cohort study. <i>BMJ Open</i> 2012;2(1):e000760.
26.	Dasbach EJ, Klein R, Klein BE, Moss SE. Self-rated health and mortality in people with diabetes. <i>Am J Public Health</i> 1994;84(11):1775-9.
27.	Prosper MH, Moczulski VL, Qureshi A. Obesity as a predictor of self-rated health. <i>Am J Health Behav</i> 2009;33(3):319-29.
28.	Haffner SM. Relationship of metabolic risk factors and development of cardiovascular disease and diabetes. <i>Obesity (Silver Spring)</i> 2006;14 Suppl 3:121S-27S.
29.	Krause NM, Jay GM. What do global self-rated health items measure? <i>Med Care</i> 1994;32(9):930-42.
30.	Bailis DS, Segall A, Chipperfield JG. Two views of self-rated general health status. <i>Soc. Sci.</i> <i>Med.</i> 2003;56(2):203-17.
31.	Gregg EW, Gu Q, Cheng YJ, Narayan KM, Cowie CC. Mortality trends in men and women with diabetes, 1971 to 2000. <i>Ann. Intern. Med.</i> 2007;147(3):149-55.
32.	Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. <i>Endocr Relat Cancer</i> 2009;16(4):1103-23.
33.	Layes A, Asada Y, Kepart G. Whiners and deniers - What does self-rated health measure? <i>Soc. Sci. Med.</i> 2011.
34.	Benyamini Y, Blumstein T, Lusky A, Modan B. Gender differences in the self-rated health- mortality association: is it poor self-rated health that predicts mortality or excellent self- rated health that predicts survival? <i>Gerontologist</i> 2003;43(3):396-405; discussion 372-5.
35.	Vadla D, Bozikov J, Akerstrom B, Cheung WY, Kovacic L, Masanovic M, et al. Differences in healthcare service utilisation in elderly, registered in eight districts of five European countries. <i>Scand J Public Health</i> 2011;39(3):272-9.
36.	Jylha M, Guralnik JM, Ferrucci L, Jokela J, Heikkinen E. Is self-rated health comparable across cultures and genders? J. Gerontol. B. Psychol. Sci. Soc. Sci. 1998;53(3):S144-52.
37.	Pencina MJ, D'Agostino RB, Sr., D'Agostino RB, Jr., Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. <i>Stat. Med.</i> 2008;27(2):157-72; discussion 207-12.
	20

Appendix

All questionnaires were standardized to fit the question (with four response alternatives):

How satisfied are you today with your health?

1 Excellent

- 2 Good
- 3 Moderate
- 4 Poor

Description of the original questions and how they were standardized:

Bilthoven 1993-94

Question: What do you think about your health in general?

Response alternatives	Standardized
1 Excellent	1 Excellent
2 Good	2 Good
3 Reasonable	3 Moderate
4 Mediocre	4 Poor
5 Poor	4 Poor
9 More than 1 option indicated	Missing value

Bilthoven 1995-97

Question: What do you think about your health in general?

Response alternatives	Standardized
1 Excellent	1 Excellent
2 Very good	2 Good
3 Good	2 Good
4 Reasonable	3 Moderate
5 Mediocre	4 Poor
9 More than 1 option indicated	Missing value

Cambridge

Question: How would you rate your general health?

Response alternatives	Standardized
1 Excellent	1 Excellent
2 Good	2 Good
3 Moderate	3 Moderate

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

4 Poor

4 Poor

Heidelberg

Question: On the whole, how satisfied are you today with your health?

Response alternatives	Standardized
1 Very satisfied	1 Excellent
2 More satisfied	2 Good
3 More dissatisfied	3 Moderate
4 Very dissatisfied	4 Poor
8 Do not know	Missing value

Potsdam

Question: On the whole, how satisfied are you today with your health?

Response alternatives	Standardized
1 Very satisfied	1 Excellent
2 More likely satisfied	2 Good
3 More likely dissatisfied	3 Moderate
4 Very dissatisfied	4 Poor
8 Do not know	Missing value

Umeå

Question: How do you judge that your state of health has been in the last year?

Response alternatives	Standardized
1 Very well	1 Excellent
2 Quiet well	2 Good
3 Fairly well	3 Moderate
4 Quiet bad	4 Poor
5 Bad	4 Poor
9 Inconsistent answer	Missing value



BMJ Open

STROBE Statement-checklist of items that should be included in reports of observational studies

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract
		(b) Provide in the abstract an informative and balanced summary of what was done
		and what was found
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
Objectives	3	State specific objectives, including any prespecified hypotheses
Methods		
Study design	4	Present key elements of study design early in the paper
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment,
		exposure, follow-up, and data collection
Participants	6	(a) Cohort study—Give the eligibility criteria, and the sources and methods of
		selection of participants. Describe methods of follow-up
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of
		case ascertainment and control selection. Give the rationale for the choice of cases
		and controls
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of
		selection of participants
		(b) Cohort study—For matched studies, give matching criteria and number of
		exposed and unexposed
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of
		controls per case
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect
		modifiers. Give diagnostic criteria, if applicable
Data sources/	8*	For each variable of interest, give sources of data and details of methods of
measurement		assessment (measurement). Describe comparability of assessment methods if there
		is more than one group
Bias	9	Describe any efforts to address potential sources of bias
Study size	10	Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable,
		describe which groupings were chosen and why
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding
		(b) Describe any methods used to examine subgroups and interactions
		(c) Explain how missing data were addressed
		(d) Cohort study—If applicable, explain how loss to follow-up was addressed
		Case-control study—If applicable, explain how matching of cases and controls was
		addressed
		Cross-sectional study—If applicable, describe analytical methods taking account of
		sampling strategy
		(<u>e</u>) Describe any sensitivity analyses
Continued on next page		

Participants 13*		(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible,	
I I I I I		examined for eligibility, confirmed eligible, included in the study, completing follow-up, and	
		analysed	
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive 14* data		(a) Give characteristics of study participants (eg demographic, clinical, social) and information	
		on exposures and potential confounders	
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) Cohort study—Summarise follow-up time (eg, average and total amount)	
Outcome data 1		Cohort study—Report numbers of outcome events or summary measures over time	
		Case-control study-Report numbers in each exposure category, or summary measures of	
		exposure	
		Cross-sectional study-Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their	
		precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and	
		why they were included	
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningfu	
		time period	
Other analyses 17		Report other analyses done-eg analyses of subgroups and interactions, and sensitivity	
		analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	
Limitations 1	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision.	
		Discuss both direction and magnitude of any potential bias	
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity	
		of analyses, results from similar studies, and other relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	
Other informati	on		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable,	
		for the original study on which the present article is based	

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.



Self-rated Health and Type 2 Diabetes Risk in the EPIC-InterAct Study: a case-cohort study

Journal:	BMJ Open
Manuscript ID:	bmjopen-2012-002436.R1
Article Type:	Research
Date Submitted by the Author:	30-Jan-2013
Complete List of Authors:	Wennberg, Patrik; Umeå University, Public Health and Clinical Medicine, Family Medicine Rolandsson, Olov; Umeå University, Public Health and Clinical Medicine, Family Medicine van der A, Daphne; National Institute for Public Health and the Environment, Centre for Prevention and Health Services Research Spijkerman, Annemieke; National Institute for Public Health and the Environment, Centre for Prevention and Health Services Research Kaaks, Rudolf; German Cancer Research, CenterDivision of Cancer Epidemiology Boeing, Heiner; German Institute of Human Nutrition Potsdam-Rehbrücke, Department of Epidemiology Feller, Silke; German Institute of Human Nutrition Potsdam-Rehbrücke, Department of Epidemiology Bergmann, Manuela; German Institute of Human Nutrition Potsdam-Rehbrücke, Department of Epidemiology Bargmann, Manuela; German Institute of Human Nutrition Potsdam-Rehbrücke, Department of Epidemiology Bargmann, Manuela; German Institute of Human Nutrition Potsdam-Rehbrücke, Department of Epidemiology Langenberg, Claudia; Institute of Metabolic Science, Addenbrooke's Hospital,, MRC Epidemiology Unit Sharp, Stephen; University of Cambridge, ; Institute of Metabolic Science, Addenbrooke's Hospital, MRC Epidemiology Unit Forouhi, Nita; MRC Epidemiology Unit, Riboli, Elio; Imperial College London, Department of Epidemiology & Biostatistics, School of Public Health Wareham, Nicholas; University of Cambridge, Institute of Public Health
Primary Subject Heading :	Diabetes and endocrinology
Secondary Subject Heading:	Public health
Keywords:	DIABETES & ENDOCRINOLOGY, General diabetes < DIABETES & ENDOCRINOLOGY, PREVENTIVE MEDICINE

SCHOLARONE[™] Manuscripts

Self-rated Health and Type 2 Diabetes Risk in the EPIC-InterAct Study: a

case-cohort study

P. Wennberg 1; O. Rolandsson 1; D.L. van der A 2; A.W. Spijkerman 2; R. Kaaks 3; H. Boeing 4; S. Feller 4; M.M. Bergmann 4; C. Langenberg 5; S.J. Sharp 5; N. Forouhi 5; E. Riboli 6; N. Wareham 5

1. Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden; 2. National Institute for Public Health and the Environment, Centre for Prevention and Health Services Research, Bilthoven, The Netherlands; 3. Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 4. Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbrücke, Nuthetal, Germany; 5. MRC Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, United Kingdom; 6. Department of Epidemiology & Biostatistics, School of Public Health, Imperial College London, London, United Kingdom.

Correspondence: P. Wennberg

Address: Portstigen 24, 931 51 Skellefteå, Sweden

Fax: +46 90 776883, Telephone: +46 90 7851423

E-mail: patrik.wennberg@fammed.umu.se

Key words: Type 2 diabetes, self-rated health, prevention, case-cohort

Word count (main text): 3533

Word count (abstract): 260

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if accepted) to be published in BMJ Open and any other BMJPGL products to exploit all subsidiary rights, as set out in our licence (http://group.bmj.com/products/journals/instructions-for-

authors/wholly owned licence.pdf) and the Corresponding Author accepts and understands that any supply made under these terms is made by BMJPGL to the Corresponding Author.

> For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Abstract

Objectives To investigate the association between self-rated health and risk of type 2 diabetes and whether the strength of this association is consistent across five European centres.

Design Population-based prospective case-cohort study.

Setting Enrolment took place between 1992 and 2000 in five European centres (Bilthoven, Cambridge, Heidelberg, Potsdam, Umeå).

Participants Self-rated health was assessed by baseline questionnaire in 3,399 incident type 2 diabetic case participants and a centre-stratified subcohort of 4,619 individuals from the EPIC-InterAct study which was drawn from a total cohort of 340,234 participants in the European Prospective Investigation into Cancer and Nutrition (EPIC).

Primary outcome measure Prentice-weighted Cox regression was used to estimate centre-specific hazard ratios (HRs) and 95% confidence intervals (CIs) for incident type 2 diabetes controlling for age, sex, centre, education, BMI, smoking, alcohol consumption, energy intake, physical activity, and hypertension. The centre-specific HRs were pooled across centres by random effects meta-analysis.

Results Low self-rated health was associated with a higher hazard of type 2 diabetes after adjusting for age and sex (pooled HR 1.67, 95% CI 1.48 to 1.88). After additional adjustment for health-related variables including BMI, the association was attenuated but remained statistically significant (pooled HR 1.29, 95% CI 1.09 to 1.53). I² index for heterogeneity across centres was 13.3% (p=0.33).

Conclusions Low self-rated health was associated with a higher risk of type 2 diabetes. The association could be only partly explained by other health-related variables, of which obesity was the strongest. We found no indication of heterogeneity in the association between self-rated health and type 2 diabetes mellitus across the European centres.

Article Summary

Article focus

- Self-rated health has been widely used as a global health measure. Several cross-sectional studies have suggested an association between low self-rated health and type 2 diabetes mellitus.
- We aimed to prospectively investigate the association between self-rated health and risk of type 2 diabetes and whether the strength of this association is consistent across five European centres. A population-based case-cohort study design was used in the study.

Key messages

- Results from this study provide some evidence that low self-rated health is associated with a higher risk of type 2 diabetes mellitus. The association could be only partly explained by other health-related variables, of which obesity was the strongest.
- We found no indication of heterogeneity in the association between self-rated health and type 2 diabetes mellitus across centres.

Strength and limitations

- The study used a thorough ascertainment and verification of type 2 diabetes mellitus cases and included populations from four different European countries.
- The assessment of self-rated health differed somewhat between centres regarding the construct (formulation, response alternatives and time frames) of the self-rated health question.

Introduction

The prevalence of type 2 diabetes mellitus (T2DM) worldwide has more than doubled since 1980.¹ In 2010, it was estimated that over 250 million people suffered from T2DM.² Several risk factors have been identified (e.g. age, BMI, family history and physical inactivity) but the aetiology of T2DM is complex and still largely unknown. Selfrated health (SRH) is a subjective measure of health usually defined by responses to a single question such as "How do you rate your health?". SRH is suggested to capture physical, psychological and social aspects that may be difficult to assess by objective health measurements³. Furthermore, SRH has been associated with "bodily sensations and symptoms that can reflect disease in clinical or pre-clinical stages".⁴⁻⁵ Individuals with poor SRH tend to have higher mortality, 3^{6} poorer physical activity and higher health care utilization⁸ than individuals rating their health as excellent or good. It is likely that individuals with poor SRH face larger or different barriers to adopt a healthy lifestyle, which may be of relevance to how prevention efforts should be targeted. Several cross-sectional studies in different populations have reported associations between poor SRH and prevalent diabetes⁹⁻¹¹ or glucometabolic disturbance.¹² The primary aim of this study was to investigate the association between SRH and risk of T2DM. As a secondary aim, we investigated whether the strength of this association was consistent across five European centres. A few previous prospective studies have evaluated the association between SRH and incidence of T2DM. A study by Tapp et al.¹³ showed that poorer SRH is associated with newly diagnosed T2DM after a five year follow-up¹³, but the study was limited by high loss to follow-up. In a recent study, Latham and Peek found that SRH was a significant predictor for six major chronic diseases, including diabetes, among late midlife U.S. adults.¹⁴ However, the outcome assessment in the study was based on self-reports, which makes the measurement susceptible for misclassification. The EPIC-InterAct Study is a large case-cohort study with thorough ascertainment and verification of T2DM that provides an ideal setting to investigate the association between SRH and T2DM across several European countries.

Methods

Study population

The InterAct Project was initiated to investigate how genetic and lifestyle behavioural factors, particularly diet and physical activity, interact on the risk of developing diabetes and how knowledge about such interactions may be translated into preventive action. The EPIC-InterAct case-cohort study was nested in the European Prospective Investigation into Cancer and Nutrition (EPIC), which in total consists of 519,978 men and women across Europe.¹⁵ Out of these, 340,234 participants were eligible for the EPIC-InterAct study, which includes centres from eight different European countries (Denmark, France, Germany, Italy, the Netherlands, Spain, Sweden and the United Kingdom). A detailed description of the study design and methods can be found elsewhere.¹⁶ In the present analysis we only included centres that had baseline data available on self-rated health (Germany: Heidelberg and Potsdam; the U.K.: Cambridge; the Netherlands: Bilthoven; Sweden: Umeå). Participants were enrolled between 1992 and 2000. An overview of the five centres is presented in Table 1. Among the participants from the five centres included in this study, 3,399 incident T2DM cases and a subcohort of 4,619 individuals remainedafter exclusions (Figure 1). Due to the random nature of the case-cohort design applied in the present study, the subcohort also included 140 individuals who developed T2DM during follow-up. All participants gave written consent and the study was approved by the ethical review board of the International Agency for Research on Cancer and by the local review boards of the participating centres.

Ascertainment of T2DM cases

Incident cases of T2DM until 31 December 2007 were ascertained and verified at each EPIC centre participating in the Epic-InterAct project using follow-up questionnaires (T2DM diagnosed by a medical doctor or anti-diabetic drug use), linkage to primary and

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

secondary care registers, medication use (prescription registers), hospital admission and mortality data, and individual medical-record review at some centres. To increase the specificity of the case definition and to avoid inclusion in the study based on self-report of T2DM alone, further evidence was sought for all incident cases of T2DM. T2DM cases were included in the study only if confirmation of the diagnosis was secured from no less than two independent sources. Cases in Umeå were not ascertained by self-report, but identified via local and national diabetes and pharmaceutical registers and hence all ascertained cases were considered to be verified.¹⁶

Assessment of self-rated health

SRH was assessed at baseline using self-administered questionnaires in the native language. The questionnaires were somewhat differently formulated at each centre and were therefore standardized (described in **Appendix**). Given the low frequency of responses in the extreme categories (n=305 in the lowest category) we dichotomized the SRH variable in the analysis by combining the two highest categories (high SRH) and the two lowest categories (low SRH) in order to increase statistical power. This is also in conformity with previous research.¹⁷⁻¹⁹

Assessment of covariates

Weight and height were measured with participants not wearing shoes. Each participant's body weight was corrected for clothing worn during measurement in order to reduce heterogeneity due to protocol differences among centres.²⁰ Body mass index (BMI) was calculated, as weight (kilograms) divided by height (metres) squared. Hypertension was defined as self-reported medical history of hypertension or hypertension (based on measurements or drug use) at baseline. Further health-related variables were collected using questionnaires including questions on educational level, smoking status (current smoker versus non-smoker or ex-smoker), diet, physical activity level, alcohol consumption, and previous myocardial infarction. Physical activity (PA) was assessed

using the Cambridge index, a validated ordered categorical global index of activity derived from simple questions assessing recreational and occupational activity.²¹

Statistical analysis

The association between SRH and various baseline characteristics within the subcohort was tested using a chi-square test (for categorical variables) and a Kruskal-Wallis test (for continuous variables). Cox proportional hazards regression, modified for the case-cohort design according to the Prentice method,²² was used to estimate centre-specific hazard ratios (HRs) and 95% confidence intervals (CI) for the association between SRH and T2DM. Age was used as the primary time variable, with entry time defined as the participant's age in years at recruitment and exit time as the participant's age in years at date of diagnosis, death or censoring. The centre-specific HRs were then pooled across centres by random effects meta-analysis.

It is not clear whether SRH mechanistically operates as an indicator of some unmeasured process or as a summary of a large number of other measures.^{3 23} Therefore, a large set of covariates were considered as potential confounders and included in models to determine pooled HRs at different levels of adjustment. All models were adjusted for age and sex. Each model was then further adjusted for the other health-related variables, one at a time and finally, all potential confounders in the same model. Education level, smoking status, physical activity and hypertension were included as categorical variables, whereas BMI, alcohol consumption and energy intake were included as continuous variables. I^2 – the percentage of variation between centres due to heterogeneity – was calculated. A possible interaction between SRH and sex on T2DM incidence was tested by introducing an interaction term in the regression analysis. We conducted a sensitivity analysis by excluding participants who were diagnosed with T2DM within two years of follow-up. In a second sensitivity analysis we excluded all participants with history of myocardial infarction at baseline. To investigate the impact of excluding 323 T2DM cases and 405 members of the subcohort with missing data on covariates, a third sensitivity

BMJ Open

analysis was conducted by multiple imputation of missing data considered missing at random (based on 5, 10 and 50 imputations) in cases and non-cases. For each variable with missing data, a predictive model was created among participants with no missing data; that model was then used to predict values for participants who were missing those data.²⁴ All analyses were performed using Stata 11.2, except for the random effects meta-analysis which was performed using Comprehensive Meta-Analysis version 2.

Results

The mean follow-up time was 9.1 years (± 3.8). SRH by centre in incident cases of T2DM and subcohort individuals is presented in **Table 2. Table 3** shows the baseline characteristics of individuals in the subcohort by categories of SRH. Participants with low SRH were younger, had lower educational level and a higher BMI than participants with high SRH. Moreover, participants with low SRH were more often smokers, less physically active, had lower alcohol consumption and estimated reported energy intake, and more frequently had hypertension and a history of myocardial infarction than persons with high SRH.

In a model with adjustment for age and centre, low SRH was associated with a higher hazard of T2DM (HR 1.67, 95% CI 1.48 to 1.88) (**Table 4**). We found no significant interaction between SRH and sex on T2DM incidence (*p*=0.54) and the analyses were therefore not stratified by sex. The strength of the association between SRH and T2DM was mainly unaffected by adjustment for smoking, alcohol consumption and estimated reported energy intake. Adjustment for other health-related variables, BMI in particular, led to attenuation of the association (adding BMI to the model attenuated the pooled HR to 1.38, 95% CI 1.19 to 1.60). In a final model with adjustment for age, sex, education, BMI, smoking, physical activity, alcohol consumption, estimated reported energy intake and hypertension, the association was attenuated but remained significant (HR 1.29, 95% CI 1.09 to 1.53). The centre-specific HRs and the pooled HR based on the final

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

 model are presented in **Figure 2**. We found no indication of heterogeneity in the association between SRH and T2DM across centres (I^2 index 13.3%, p=0.33).

In a first sensitivity analysis we excluded participants who were diagnosed with T2DM within two years of follow-up (n=398). These exclusions had only minor effect on the pooled HR (1.29, 95% CI 1.08 to 1.55, adjusted for the variables in the final model). The number of participants with history of myocardial infarction was low (n=202) and the multivariate model did not fit when this covariate was included. Thus, in the second sensitivity analysis we excluded all participants with a history of myocardial infarction at baseline. This did not change the conclusions (pooled HR 1.27, 95% CI 1.08 to 1.50, adjusted for the variables in the final model). Because of missing data on covariates, 323 T2DM cases and 405 members of the subcohort were excluded from analyses. As a third sensitivity analysis, multiple imputations of these data, assuming missingness at random, were conducted. No significant differences in results were found in datasets based on 5, 10 or 50 imputations, compared to the original dataset. Therefore, it seems unlikely that the results are biased due to missing data.

Discussion

In this prospective case-cohort study we found that low SRH was associated with a higher risk of T2DM. The association was partly explained by other health-related variables, particularly BMI. A somewhat unexpected finding was that the association between SRH and T2DM was mainly unaffected by adjustment for smoking, alcohol consumption and estimated reported energy intake. We found no indication of heterogeneity in the association between SRH and T2DM across the European centres.

SRH has been widely used as a global health measure. Previous studies on general populations have shown that there is a strong relationship between SRH and mortality, even after controlling for sociodemographic factors, objective measures of health status, and health behaviours ^{6 25}. A few studies have investigated the association between SRH and mortality in populations of diabetes patients with results similar to those of general

BMJ Open

populations ^{18 26-27}. SRH and prevalent diabetes have been associated in several crosssectional studies ^{9-12 28}. However, cross-sectional studies are limited by their inability to study the temporal sequence of exposure and disease. Furthermore, these studies have not separated type 2 and type 1 diabetes.

Any causality cannot be established by an observational study, but the findings in this prospective study imply that there is a dominant direction of this association from low SRH to T2DM (i.e. a temporal relationship). We have only found two previous prospective studies of the association between SRH and T2DM in large general populations. In the Australian Diabetes Obesity and Lifestyle study, Tapp et al. ¹³ found that participants with newly diagnosed diabetes had reported impaired general health before the onset of T2DM. The study was limited by a shorter follow-up (5 years) and they did not present any sensitivity analysis with exclusion of participants, who were diagnosed with T2DM shortly after baseline, which makes a bidirectional association more likely. In our study, with a mean follow-up of over 9 years, the association between SRH and T2DM remained when we excluded participants who were diagnosed with T2DM within two years of follow-up. Recently, Latham and Peek published a report from the Health and Retirement Study, a longitudinal survey of a U.S. midlife cohort.¹⁴ They found that SRH predicted diabetes as well as coronary heart disease, stroke, lung disease, and arthritis but not cancer. A weakness in the study was that the outcome measurement was based on self-reports. Our study supports this previous prospective research by showing an association between SRH and T2DM also when a strict verification procedure for outcome measurement is applied.

In the present study, low SRH was associated with a higher BMI which is in line with previous research. In a study investigating the relationship between self-rated health and obesity, Prosper et al. found that obese individuals had a 3-fold greater odds of reporting reduced health compared to individuals with normal weight or overweight. As obesity is also considered to be a major risk factor for diabetes ²⁹, obesity is likely to explain a substantial part of the association between low SRH and T2DM. Thus, it is not

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

surprising that BMI may act as an important confounder in the association between SRH and T2DM in this study -or as a mediator since SRH and obesity might be on the same causal pathway. More surprising was the fact that participants with low SRH had lower alcohol consumption and estimated reported energy intake. These findings are not easily explained and raise questions regarding the criteria for self-assessment. Previous research on occupational cohorts has suggested that SRH principally reflects physical and mental health problems and to a lesser extent age, early life factors, family history, sociodemographic variables, psychosocial factors, and health behaviours ²³. One study that used in-depth interviews found that the same frame of reference is not used by all respondents in answering this question ³⁰. Some study participants think about specific health problems when asked to rate their health, whereas others think in terms of either general physical functioning or health behaviours. In our study, the question for SRH referred to different time frames (e.g. satisfaction with health today in Germany and perception of health over the last year in Sweden). SRH has shown to be stable over time in population-based studies, suggesting that a considerable component of SRH reflects an aspect of one's enduring self-concept and to a lesser extent a spontaneous assessment of one's health status ³¹. Thus, the impact of different time frames on SRH assessment is likely to be small.

Compared to studies of SRH with mortality outcomes in individuals with diabetes ^{18 26-27} the strength of the SRH association (with T2DM incidence) found in the present study was weak. There may be several explanations for this. It has been shown that diabetes patients have higher mortality rates from several causes ³², including cancer ³³. It is likely that the comparatively strong association between SRH and mortality is due to a higher ability for SRH to summarize global health risk among diabetes patients than specifically metabolic risk in a general population. It is also possible that SRH is more susceptible to "reporting behaviour" (i.e. how optimistic or pessimistic people are about their health) ³⁴ in a generally healthier population compared to subjective health ratings later on in the disease process.

BMJ Open

Previous findings suggest that there may be sex differences in the SRH-mortality association ³⁵ but we found no sex difference in the association between SRH and T2DM. SRH may also vary across countries ³⁶. In the present study, it is likely that the differences in SRH across centres to some extent can be explained by different sampling strategies and age distributions at different centres. We did not find support for heterogeneity in the association between SRH and T2DM across centres in this study. However, the study was restricted to countries in northern Europe. It is therefore not clear how these findings are generalisable to other populations. Moreover, in Heidelberg and Potsdam, the SRH question was assessed in terms of satisfaction with health and in the other centres in terms of perception of health, which may have had an influence on the distribution of responses. There were also some differences in response alternatives between centres. To some extent these differences were handled by standardization but the differences in the construct of the SRH question between centres are limitations to this study, particularly to the analysis of heterogeneity.

Strengths of the present study include the thorough ascertainment and verification of T2DM cases. Moreover, cultural differences may also have an impact on SRH, even within Europe and we included populations from four different European countries ³⁷. Several limitations of the study have already been listed, such as different construct of the SRH question and the restriction to countries in northern Europe. We would also like to point out that it is possible that participants reporting low SRH at baseline were more likely to seek medical advice during follow-up and hence were more likely to be tested for diabetes (detection bias). If this was the case, the study may have overestimated the risk of T2DM associated with low SRH.

In our study, part of the SRH-T2DM association seemed to be explained by medical history as well as lifestyle variables. SRH may therefore be considered as a summary health measure – also for metabolic health. If there is access to several of the established risk factors for diabetes, SRH is not likely to add more than marginally to risk prediction on top of the conventional risk factors. However, whether SRH adds

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

predictive value over and above established risk factors needs to be further analysed using adequate methods ³⁸.

In conclusion, results from this prospective case-cohort study provide some evidence that low self-rated health is associated with a higher risk of type 2 diabetes mellitus. The association could be only partly explained by other health-related variables, of which obesity was the strongest.

Acknowledgments

We thank all EPIC participants and staff for their contribution to the study. We thank Nicola Kerrison (MRC Epidemiology Unit, Cambridge) for managing the data for the InterAct Project.

Footnotes

Contributors: PW had access to all data for this study, analysed the data, drafted the manuscript and is the guarantor. All authors qualify for authorship according to BMJ Open criteria. They have all contributed to conception and design, and interpretation of data, revising the article critically for important intellectual content and final approval of the version to be published.

Competing interests: All authors have completed the Unified Competing Interest form at www.icmje.org/coi disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisation that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Funding: Funding for the InterAct project was provided by the EU FP6 programme [grant number Integrated Project LSHM_CT_2006_037197]. The funder had no role in study

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

		Baseline collection						
Centre	Description of source population	n	Women (%)	5 th and 95 th age percentiles				
Bilthoven	Participants were invited as age- and sex-stratified random sample of the general population	22,715	55	23–58				
Cambridge	Volunteers were invited as a random sample of the population listed at general practitioners	30,441	55	45–74				
Heidelberg	Volunteers were invited from the general population	25,540	53	37–63				
Potsdam	Volunteers were invited from the general population	27,548	60	36–64				
Umeå	Participants were invited as a random sample of the population	25,728	52	30–60				

Table 1 Overview of the five centres included in the study from the EPIC-InterAct study.

design, data collection and analysis, decision to publish, or preparation of the manuscript. In addition, InterAct investigators acknowledge funding from the following agencies: DLvdA and AMWS: Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); RK: Deutsche Krebshilfe.

Ethical approval: The study was approved by the IARC Institutional Review Board and by the local review boards of the participating centers.

Data sharing: No additional data available.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

Table 2 Self-rated health by centre in 3,399 incident cases of type 2 diabetes mellitus and 4,619 participants in the subcohort in the EPIC-InterAct study. Data shown are numbers of individuals (percentage).

		d health			
Centre		Hi	Lo	w	
		Excellent	Good	Moderate	Poor
Bilthoven	Cases	13 (4.3)	184 (61.5)	73 (24.4)	29 (9.7)
	Subcohort	52 (9.0)	403 (70.0)	101 (17.5)	21 (3.6)
Cambridge	Cases	92 (12.3)	428 (57.1)	206 (27.5)	24 (3.2)
	Subcohort	159 (16.2)	624 (63.4)	170 (17.4)	23 (2.3)
Heidelberg	Cases	173 (23.1)	395 (52.8)	156 (20.9)	24 (3.2)
	Subcohort	286 (32.9)	448 (51.5)	125 (14.4)	11 (1.3)
Potsdam	Cases	118 (15.2)	460 (59.4)	171 (22.1)	26 (3.4)
	Subcohort	274 (23.1)	721 (60.9)	164 (13.9)	25 (2.1)
Umeå	Cases	155 (18.7)	369 (44.6)	236 (28.5)	67 (8.1)
	Subcohort	265 (26.2)	477 (47.1)	215 (21.2)	55 (5.4)

Table 3 Baseline characteristics of subcohort individuals in the EPIC-InterAct study by categories of self-rated health. Data are presented as mean and standard deviations (SD) for continuous variables and percentages and frequencies for categorical variables.

	Self-rated health										
		High				Low					
	Excel	ent	Goo	Good		Moderate		Poor			
	Mean/%	SD/N	Mean/%	SD/N	Mean/%	SD/N	Mean/%	SD/N	overall difference [*]		
Age (years)	48.8	10.3	50.5	11.1	51.7	10.9	50.3	10.2	<0.001		
Sex (% men)	42.8	443	45.2	1208	44.8	347	37.8	51	0.24		
Educational level (%)									<0.001		
Primary school or none	19.2	194	24.4	635	37.9	287	30.8	40			
Technical/ professional school	34.6	351	35.0	910	29.6	224	32.3	42			
Secondary school	14.9	151	14.2	369	14.4	109	18.5	24			
Higher (incl. university degree)	31.3	317	26.4	688	18.1	137	18.5	24			
BMI (kg/m²)	24.8	3.4	25.5	4.0	26.2	4.5	25.6	5.4	<0.001		
Smoking status (%)									< 0.001		
Never	52.1	540	46.6	1246	41.7	323	40.7	55			
Former	27.5	285	30.1	804	30.1	233	23.7	32			
Current	18.8	195	21.0	561	26.1	202	32.6	44			
Unknown	1.5	16	2.3	62	2.2	17	3.0	4			
Physical activity (%)									< 0.001		
Inactive	15.9	160	21.3	548	31.1	231	43.3	52			
Moderately inactive	33.2	335	31.7	818	28.8	214	29.2	35			
Moderately active	25.5	257	26.8	689	21.8	162	15.0	18			
Active	25.5	257	20.2	521	18.2	135	12.5	15			
Alcohol consumption (g/d)	11.5	16.2	10.8	15.2	9.2	15.4	5.6	9.8	<0.001		
Total energy intake (kcal)	2016.6	649.7	2056.7	618.3	2009.4	617.3	1928.3	617.9	0.007		
Hypertension (%)	16.0	165	22.8	600	32.7	245	33.3	44	<0.001		
History of myocardial infarction (%)	0.4	4	1.5	40	3.6	28	3.7	5	<0.001		

*Comparing excellent, good, moderate, and poor self-rated health

BMJ Open

 Table 4 Pooled hazard ratios of incident T2DM comparing low (moderate or poor) versus high (excellent or good) self-related health.

	High self-rated health	Low self-rated health
	Pooled HR (95% CI)	Pooled HR (95% CI)*
Model 1: Adjusted for age and sex	1.00 (referent)	1.67 (1.48 to 1.88)
Model 1 + education	1.00 (referent)	1.60 (1.42 to 1.81)
Model 1 + BMI	1.00 (referent)	1.38 (1.19 to 1.60)
Model 1 + smoking	1.00 (referent)	1.67 (1.48 to 1.89)
Model 1 + physical activity	1.00 (referent)	1.59 (1.41 to 1.80)
Model 1 + alcohol consumption	1.00 (referent)	1.67 (1.48 to 1.89)
Model 1 + energy intake	1.00 (referent)	1.67 (1.48 to 1.88)
Model 1 + hypertension	1.00 (referent)	1.48 (1.31 to 1.69)
Model 1 + all covariates above	1.00 (referent)	1.29 (1.09 to 1.53)

*Pooled hazard ratios calculated using a centre-stratified approach in combination with a random effects meta-analysis.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

FIGURE LEGENDS

Figure 1 Overview of the five centres included in the study from the EPIC-InterAct study.

Figure 2 Centre-specific and pooled hazard ratios of incident T2DM adjusted for the variables in the final model (age, sex, education, BMI, smoking, physical activity, alcohol consumption, energy intake and hypertension).

References

- 1. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. *Lancet* 2011;378(9785):31-40.
- 2. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. *Diabetes Res Clin Pract* 2010;87(1):4-14.
- 3. Idler EL, Benyamini Y. Self-rated health and mortality: a review of twenty-seven community studies. *J. Health Soc. Behav.* 1997;38(1):21-37.
- 4. Benyamini Y. Why does self-rated health predict mortality? An update on current knowledge and a research agenda for psychologists. *Psychol Health* 2011;26(11):1407-13.
- 5. Halford C, Anderzen I, Arnetz B. Endocrine measures of stress and self-rated health: a longitudinal study. *J Psychosom Res* 2003;55(4):317-20.
- 6. DeSalvo KB, Bloser N, Reynolds K, et al. Mortality prediction with a single general self-rated health question. A meta-analysis. *J Gen Intern Med* 2006;21(3):267-75.
- Mavaddat N, Kinmonth AL, Sanderson S, et al. What determines Self-Rated Health (SRH)? A cross-sectional study of SF-36 health domains in the EPIC-Norfolk cohort. J Epidemiol Community Health 2011;65(9):800-6.
- 8. DeSalvo KB, Jones TM, Peabody J, et al. Health care expenditure prediction with a single item, self-rated health measure. *Med Care* 2009;47(4):440-7.
- 9. Ramkumar A, Quah JL, Wong T, et al. Self-rated health, associated factors and diseases: a community-based cross-sectional study of Singaporean adults aged 40 years and above. *Ann. Acad. Med. Singapore* 2009;38(7):606-7.
- 10. Shadbolt B. Some correlates of self-rated health for Australian women. *Am J Public Health* 1997;87(6):951-6.
- 11. Manor O, Matthews S, Power C. Self-rated health and limiting longstanding illness: interrelationships with morbidity in early adulthood. *Int J Epidemiol* 2001;30(3):600-7.
- 12. Leosdottir M, Willenheimer R, Persson M, et al. The association between glucometabolic disturbances, traditional cardiovascular risk factors and self-rated health by age and gender: a cross-sectional analysis within the Malmo Preventive Project. *Cardiovasc Diabetol* 2011;10:118.
- 13. Tapp RJ, O'Neil A, Shaw JE, et al. Is there a link between components of health-related functioning and incident impaired glucose metabolism and type 2 diabetes? The Australian Diabetes Obesity and Lifestyle (AusDiab) study. *Diabetes Care* 2010;33(4):757-62.
- 14. Latham K, Peek CW. Self-rated health and morbidity onset among late midlife u.s. Adults. J. *Gerontol. B. Psychol. Sci. Soc. Sci.* 2013;68(1):107-16.
- 15. Riboli E, Hunt KJ, Slimani N, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. *Public Health Nutr* 2002;5(6B):1113-24.

BMJ Open

2		
3	16.	Langenberg C, Sharp S, Forouhi NG, et al. Design and cohort description of the InterAct
4		Project: an examination of the interaction of genetic and lifestyle factors on the incidence of
5		type 2 diabetes in the EPIC Study. <i>Diabetologia</i> 2011;54(9):2272-82.
6	17.	Walker JD, Maxwell CJ, Hogan DB, et al. Does self-rated health predict survival in older
7		persons with cognitive impairment? J. Am. Geriatr. Soc. 2004;52(11):1895-900.
8	18.	McEwen LN, Kim C, Haan MN, et al. Are health-related quality-of-life and self-rated health
9		associated with mortality? Insights from Translating Research Into Action for Diabetes
10		(TRIAD). Prim Care Diabetes 2009;3(1):37-42.
11	19.	Lee SJ, Moody-Ayers SY, Landefeld CS, et al. The relationship between self-rated health and
12		mortality in older black and white Americans. J. Am. Geriatr. Soc. 2007;55(10):1624-9.
13	20.	Pischon T, Boeing H, Hoffmann K, et al. General and abdominal adiposity and risk of death in
14	20.	Europe. <i>N Engl J Med</i> 2008;359(20):2105-20.
15	21.	Validity of a short questionnaire to assess physical activity in 10 European countries. <i>Eur J</i>
16 17	21.	Epidemiol 2012;27(1):15-25.
18	22	
19	22.	Barlow WE, Ichikawa L, Rosner D, et al. Analysis of case-cohort designs. <i>J Clin Epidemiol</i>
20	20	1999;52(12):1165-72.
21	23.	Singh-Manoux A, Martikainen P, Ferrie J, et al. What does self rated health measure? Results
22		from the British Whitehall II and French Gazel cohort studies. J. Epidemiol. Community Health
23		2006;60(4):364-72.
24	24.	Kenward MG, Carpenter J. Multiple imputation: current perspectives. Stat. Methods Med.
25		Res. 2007;16(3):199-218.
26	25.	Benjamins MR, Hummer RA, Eberstein IW, et al. Self-reported health and adult mortality risk:
27		an analysis of cause-specific mortality. Soc Sci Med 2004;59(6):1297-306.
28	26.	Wennberg P, Rolandsson O, Jerden L, et al. Self-rated health and mortality in individuals with
29		diabetes mellitus: prospective cohort study. BMJ Open 2012;2(1):e000760.
30	27.	Dasbach EJ, Klein R, Klein BE, et al. Self-rated health and mortality in people with diabetes.
31		Am J Public Health 1994;84(11):1775-9.
32	28.	Prosper MH, Moczulski VL, Qureshi A. Obesity as a predictor of self-rated health. Am J Health
33		Behav 2009;33(3):319-29.
34	29.	Haffner SM. Relationship of metabolic risk factors and development of cardiovascular disease
35		and diabetes. Obesity (Silver Spring) 2006;14 Suppl 3:121S-27S.
36	30.	Krause NM, Jay GM. What do global self-rated health items measure? Med Care
37 38		1994;32(9):930-42.
39	31.	Bailis DS, Segall A, Chipperfield JG. Two views of self-rated general health status. Soc. Sci.
40		Med. 2003;56(2):203-17.
40	32.	Gregg EW, Gu Q, Cheng YJ, et al. Mortality trends in men and women with diabetes, 1971 to
42		2000. Ann. Intern. Med. 2007;147(3):149-55.
43	33.	Vigneri P, Frasca F, Sciacca L, et al. Diabetes and cancer. Endocr Relat Cancer
44		2009;16(4):1103-23.
45	34.	Layes A, Asada Y, Kepart G. Whiners and deniers - What does self-rated health measure? Soc.
46		Sci. Med. 2011.
47	35.	Benyamini Y, Blumstein T, Lusky A, et al. Gender differences in the self-rated health-mortality
48	55.	association: is it poor self-rated health that predicts mortality or excellent self-rated health
49		that predicts survival? <i>Gerontologist</i> 2003;43(3):396-405; discussion 372-5.
50	36.	Vadla D, Bozikov J, Akerstrom B, et al. Differences in healthcare service utilisation in elderly,
51	50.	registered in eight districts of five European countries. Scand J Public Health 2011;39(3):272-
52		9.
53	27	
54	37.	Jylha M, Guralnik JM, Ferrucci L, et al. Is self-rated health comparable across cultures and genders? J. Gerontol. B. Psychol. Sci. Soc. Sci. 1998;53(3):S144-52.
55	20	
56 57	38.	Pencina MJ, D'Agostino RB, Sr., D'Agostino RB, et al. Evaluating the added predictive ability of
57 58		a new marker: from area under the ROC curve to reclassification and beyond. <i>Stat. Med.</i>
58 59		2008;27(2):157-72; discussion 207-12.
59 60		21
00		21

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

P. Wennberg 1; O. Rolandsson 1; D.L. van der A 2; A.W. Spijkerman 2; R. Kaaks 3; H. Boeing 4; S. Feller 4; M.M. Bergmann 4; C. Langenberg 5; S.J. Sharp 5; N. Forouhi 5; E. Riboli 6; N. Wareham 5

1. Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden; 2. National Institute for Public Health and the Environment, Centre for Prevention and Health Services Research, Bilthoven, The Netherlands; 3. Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 4. Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbrücke, Nuthetal, Germany; 5. MRC Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's idem. nited Kingdon. Hospital, Cambridge, United Kingdom; 6. Department of Epidemiology & Biostatistics, School of Public Health, Imperial College London, London, United Kingdom.

Correspondence: P. Wennberg

Address: Portstigen 24, 931 51 Skellefteå, Sweden

Fax: +46 90 776883, Telephone: +46 90 7851423

E-mail: patrik.wennberg@fammed.umu.se

Key words: Type 2 diabetes, self-rated health, prevention, case-cohort

Word count (main text): 3533426

Word count (abstract): 26047

> The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to <text><text><text> permit this article (if accepted) to be published in BMJ Open and any other BMJPGL products to exploit all subsidiary rights, as set out in our licence (http://group.bmj.com/products/journals/instructions-forauthors/wholly owned licence.pdf) and the Corresponding Author accepts and understands that any supply made under these terms is made by BMJPGL to the Corresponding Author.

Abstract

Objectives To investigate the association between self-rated health and risk of type 2 diabetes <u>and</u>-whether the strength of this association is consistent across five European <u>centres</u>.

Design Population-based prospective case-cohort study.

Setting Enrolment took place between 1992 and 2000 in five European centres (Bilthoven, Cambridge, Heidelberg, Potsdam, Umeå).

Participants Self-rated health was assessed by baseline questionnaire in 3,399 incident type 2 diabetic case participants and a centre-stratified subcohort of 4,619 individuals from the EPIC-InterAct study which was drawn from a total cohort of 340,234 participants in the European Prospective Investigation into Cancer and Nutrition (EPIC).

Primary outcome measure Prentice-weighted Cox regression was used to estimate centre-specific hazard ratios (HRs) and 95% confidence intervals (CIs) for incident type 2 diabetes controlling for age, sex, centre, education, BMI, smoking, alcohol consumption, energy intake, physical activity, and hypertension. The centre-specific HRs were pooled across centres by random effects meta-analysis.

Results Low self-rated health was associated with a higher hazard of type 2 diabetes after adjusting for age and sex (pooled HR 1.67, 95% CI 1.48 to 1.88). After additional adjustment for health-related variables including BMI, the association was attenuated but remained statistically significant (pooled HR 1.29, 95% CI 1.09 to 1.53). I² index for heterogeneity across centres was 13.3% (p=0.33).

Conclusions Low self-rated health was associated with a higher risk of type 2 diabetes. The association could be only partly explained by other health-related variables, of which obesity was the strongest. We found no indication of heterogeneity in the association between self-rated health and type 2 diabetes mellitus across the European centres.

Article Summary

Article focus

- Self-rated health has been widely used as a global health measure. Several cross-sectional studies have suggested an association between low self-rated health and type 2 diabetes mellitus.
- We aimed to prospectively investigate the association between self-rated health and risk of type 2 diabetes and whether the strength of this association is <u>consistent across five European centres</u>. A population-based case-cohort study design was used and five European centers were included-in the study.

Key messages


- Results from this study provide some evidence that low self-rated health is associated with a higher risk of type 2 diabetes mellitus. The association could be only partly explained by other health-related variables, of which obesity was the strongest.
- We found no indication of heterogeneity in the association between self-rated health and type 2 diabetes mellitus across centres.

Strength and limitations

- The study used a thorough ascertainment and verification of type 2 diabetes mellitus cases and included populations from four different European countries.
- The assessment of self-rated health differed somewhat between centres regarding the construct (formulation, response alternatives and time frames) offor the self-rated health question.

Introduction

The prevalence of type 2 diabetes mellitus (T2DM) worldwide has more than doubled since 1980.¹ In 2010, it was estimated that over 250 million people suffered from T2DM.² Several risk factors have been identified (e.g. age, BMI, family history and physical inactivity) but the aetiology of T2DM is complex and still largely unknown. Selfrated health (SRH) is a subjective measure of health usually defined by responses to a single question such as "How do you rate your health?". SRH is suggested to capture physical, psychological and social aspects that may be difficult to assess by objective health measurements³. Furthermore, SRH has been associated with "bodily sensations and symptoms that can reflect disease in clinical or pre-clinical stages".4-5 Individuals with poor self-rated health (SRH) tend to have higher mortality $^{3}_{\mu}$ ⁶ poorer physical activity⁷ and higher health care utilization⁸ than individuals rating their health as excellent or good. It is likely that individuals with poor SRH face larger or different barriers to adopt a healthy lifestyle, which may be of relevance to how prevention efforts should be targeted. Several cross-sectional studies in different populations have reported associations between poor SRH and prevalent diabetes⁹⁻¹¹ or glucometabolic disturbance.¹² The primary aim of this study was to investigate the association between SRH and risk of T2DM. As a secondary aim, we investigated whether the strength of this association was consistent across five European centres. A few To our knowledge, only one previous prospective studies have evaluatedy on the association between SRH and incidence of T2DM has been published., A study by Tapp et al.¹³ showeding that poorerreduced SRH is associated with newly diagnosed T2DM after a five year follow up_{τ}^{13} , but the However, this prospective study was limited by high loss to follow-up. In a recent study, Latham and Peek found that SRH was a significant predictor for six major chronic diseases, including diabetes, among late midlife U.S. adults.¹⁴ However, the outcome assessment in the study was based on self-reports, which makes the measurement susceptible for misclassification. The EPIC-InterAct Study is a large casecohort study with thorough ascertainment and verification of T2DM that provides an ideal



Field Code Changed

Field Code Changed

Field Code Changed

Formatted: Do not check spelling or grammar, Superscript

Formatted: Do not check spelling or grammar, Superscript

setting to investigate the association between SRH and T2DM across several European countries.

Methods

Study population

The InterAct Project was initiated to investigate how genetic and lifestyle behavioural factors, particularly diet and physical activity, interact on the risk of developing diabetes and how knowledge about such interactions may be translated into preventive action. The EPIC-InterAct case-cohort study was nested in the European Prospective Investigation into Cancer and Nutrition (EPIC), which in total consists of 519,978 men and women across Europe, 1514 Out of these, 340,234 participants were eligible for the EPIC-InterAct study, which includes centres from eight different European countries (Denmark, France, Germany, Italy, the Netherlands, Spain, Sweden and the United Kingdom). A detailed description of the study design and methods can be found elsewhere, 1615 In the present analysis we only included centres that had baseline data available on self-rated health (Germany: Heidelberg and Potsdam; the U.K.: Cambridge; the Netherlands: Bilthoven; Sweden: Umeå). Participants were 25 to 70 years old at enrolledment between 1992 and 2000. An overview of the five centres is presented in Table 1. Among the participants from the five centres included in this study, 3,399 incident T2DM cases 3,412 incident T2DM cases were identified and a subcohort of 4,6194,637 individuals remained were randomly selected after exclusions for prevalent diabetes or unknown diabetes status. Data on self rated health was available for 4,619 individuals in the subcohort and 3,399 incident T2DM cases(Figure 1). Due to the random nature of the case-cohort design applied in the present study, the subcohort also included 140 individuals who developed T2DM during follow-up. All participants gave written consent and the study was approved by the ethical review board of the International Agency for Research on Cancer and by the local review boards of the participating centres.

Field Code Changed

Field Code Changed

Ascertainment of T2DM cases

Incident cases of T2DM until 31 December 2007 were ascertained and verified at each EPIC centre participating in the Epic-InterAact project using follow-up questionnaires (T2DM diagnosed by a medical doctor or anti-diabetic drug use), linkage to primary and secondary care registers, medication use (prescription registers), hospital admission and mortality data, and individual medical-record review at some centres. To increase the specificity of the case definition and to avoid inclusion in the study based on self-report of T2DM alone, further evidence was sought for all incident cases of T2DM. T2DM cases were included in the study only if confirmation of the diagnosis was secured from no less than two independent sources. Cases in UmeaSweden were not ascertained by selfreport, but identified via local and national diabetes and pharmaceutical registers and hence all ascertained cases were considered to be verified. 1615 To increase the specificity of the case definition and to avoid inclusion in the study based on self report of T2DM alone, further evidence was sought for all incident cases of T2DM. T2DM cases the case definition and to avoid inclusion in the study based on self report of T2DM alone, further evidence was sought for all incident cases of T2DM. T2DM cases were included in the study only if confirmation of the diagnosis was secured from no less than two independent sources, including individual medical record review.

Assessment of self-rated health

SRH was assessed at baseline using self-administered questionnaires in the native language. The questionnaires were somewhat differently formulated at each centre and were therefore standardized (described in **Appendix**). Given the low frequency of responses in the extreme categories (n=305 in the lowest category) we dichotomized the SRH variable in the analysis by combining the two highest categories (high SRH) and the two lowest categories (low SRH) in <u>order to increase statistical power. This is also in</u> conformity with previous research.¹⁷⁻¹⁹¹⁶⁻¹⁸

Field Code Changed

Field Code Changed

Assessment of covariates

Weight and height were measured with participants not wearing shoes. Each participant's body weight was corrected for clothing worn during measurement in order to reduce heterogeneity due to protocol differences among centres.²⁰¹⁹ Body mass index (BMI) was calculated, as weight (kilograms) divided by height (metres) squared. Hypertension was defined as self-reported medical history of hypertension or hypertension (based on measurements or drug use) at baseline. Further health-related variables were collected using questionnaires including questions on educational level, smoking status (current smoker versus non-smoker or ex-smoker), diet, physical activity level, alcohol consumption, and previous myocardial infarction. Physical activity (PA) was assessed using the Cambridge index, a validated ordered categorical global index of activity derived from simple questions assessing recreational and occupational activity.²¹²⁰

Statistical analysis

The association between SRH and various baseline characteristics within the subcohort was tested using a chi-square test (for categorical variables) and a Kruskal-Wallis test (for continuous variables). Cox proportional hazards regression, modified for the case-cohort design according to the Prentice method,²²²⁴ was used to estimate centre-specific hazard ratios (HRs) and 95% confidence intervals (CI) for the association between SRH and T2DM. Age was used as the primary time variable, with entry time defined as the participant's age in years at recruitment and exit time as the participant's age in years at date of diagnosis, death or censoring. The centre-specific HRs were then pooled across centres by random effects meta-analysis.

It is not clear whether SRH mechanistically operates as an indicator of some unmeasured process or as a summary of a large number of other measures, $\frac{3}{2}$ $\frac{233}{22}$ Therefore, a large set of covariates were considered as potential confounders and included in models to determine pooled HRs at different levels of adjustment. All models were adjusted for age and sex. Each model was then further adjusted for the other health-related variables, one at a time and finally, all potential confounders in the same model. Education level,

Field Code Changed

BMJ Open

smoking status, physical activity and hypertension were included as categorical variables, whereas BMI, alcohol consumption and energy intake were included as continuous variables. *I*² – the percentage of variation between centres due to heterogeneity – was calculated. A possible interaction between SRH and sex on T2DM incidence was tested by introducing an interaction term in the regression analysis. We conducted a sensitivity analysis by excluding participants who were diagnosed with T2DM within two years of follow-up. In a second sensitivity analysis we excluded all participants with history of myocardial infarction at baseline. To investigate the impact of excluding 323 T2DM cases and 405 members of the subcohort withef missing data on covariates, a third sensitivity analysis was conducted by multiple imputation of missing data considered missing at random (based on 5, 10 and 50 imputations) in cases and non-cases. For each variable with missing data, a predictive model was created among participants with no missing data; that model was then used to predict values for participants who were missing those data, ²⁴²³ All analyses were performed using Stata 11.2, except for the random effects meta-analysis which was performed using Comprehensive Meta-Analysis version 2.

Field Code Changed

Results

The mean follow-up time was 9.1 years (± 3.8). SRH by centre in incident cases of T2DM and subcohort individuals is presented in **Table 24**. **Table 32** shows the baseline characteristics of individuals in the subcohort by categories of SRH. Participants with low SRH were younger, had lower educational level and a higher BMI than participants with high SRH. Moreover, participants with low SRH were more often smokers, less physically active, had lower alcohol consumption and estimated reported energy intake, and more frequently had hypertension and a history of myocardial infarction than persons with high SRH.

In a model with adjustment for age and centre, low SRH was associated with a higher hazard of T2DM (HR 1.67, 95% CI 1.48 to 1.88) (**Table 43**). We found no significant

interaction between SRH and sex on T2DM incidence (p=0.54) and the analyses were therefore not stratified by sex. The strength of the association between SRH and T2DM was mainly unaffected by adjustment for smoking, alcohol consumption and estimated reported energy intake. Adjustment for other health-related variables, BMI in particular, led to attenuation of the association (adding BMI to the model attenuated the pooled HR to 1.38, 95% CI 1.19 to 1.60). In a final model with adjustment for age, sex, education, BMI, smoking, physical activity, alcohol consumption, estimated reported energy intake and hypertension, the association was attenuated but remained significant (HR 1.29, 95% CI 1.09 to 1.53). The centre-specific HRs and the pooled HR based on the final model are presented in **Figure 24**. We found no indication of heterogeneity in the association between SRH and T2DM across centres (I² index 13.3%, p=0.33).

In a first sensitivity analysis we excluded participants who were diagnosed with T2DM within two years of follow-up (n=398). These exclusions had only minor effect on the pooled HR (1.29, 95% CI 1.08 to 1.55, adjusted for the variables in the final model). The number of participants with history of myocardial infarction was low (n=202) and the multivariate model did not fit when this covariate was included. Thus, in the second sensitivity analysis we excluded all participants with a history of myocardial infarction at baseline. This did not change the conclusions (pooled HR 1.27, 95% CI 1.08 to 1.50, adjusted for the variables in the final model). Because of missing data on covariates, 323 T2DM cases and 405 members of the subcohort were excluded from analyses. As a third sensitivity analysis, multiple imputations of these data, assuming missingness at random, were conducted. No significant differences in results were found in datasets based on 5, 10 or 50 imputations, compared to the original dataset. Therefore, it seems unlikely that the results are biased due to missing data.

Discussion

In this prospective case-cohort study we found that low SRH was associated with a higher risk of T2DM. The association was partly explained by other health-related

BMJ Open

variables, particularly BMI. <u>A somewhat unexpected finding was that the association</u> <u>between SRH and T2DM was mainly unaffected by adjustment for smoking, alcohol</u> <u>consumption and estimated reported energy intake.</u> We found no indication of heterogeneity in the association between SRH and T2DM across the European centres.

SRH has been widely used as a global health measure. Previous studies on general populations have shown that there is a strong relationship between SRH and mortality, even after controlling for sociodemographic factors, objective measures of health status, and health behaviours $\frac{6.256-24}{.}$. A few studies have investigated the association between SRH and mortality in populations of diabetes patients with results similar to those of general populations $\frac{18.26-2717-25-26}{.}$. SRH and prevalent diabetes have been associated in several cross-sectional studies $\frac{9-12.289-12-27}{.}$. However, cross-sectional studies are limited by their inability to study the temporal sequence of exposure and disease. Furthermore, these studies have not separated type 2 and type 1 diabetes.

Any causality cannot be established by an observational study, but the findings in this prospective study imply that there is a dominant direction of this association from low SRH to T2DM (i.e. a temporal relationship). We have only found <u>twoone</u> previous prospective stud<u>iesy</u> of the association between SRH and T2DM in—a large general population<u>s</u>. In the Australian Diabetes Obesity and Lifestyle study, Tapp et al. ¹³ found that participants with newly diagnosed diabetes had reported impaired general health before the onset of T2DM. The study was limited by a shorter follow-up (5 years) and they did not present any sensitivity analysis with exclusion of participants, who were diagnosed with T2DM shortly after baseline, which makes a bidirectional association more likely. Furthermore, the study was limited by a low follow up response rate.In our study, with a mean follow-up of over 9 years, the association between SRH and T2DM within two years of follow-up. Recently, Latham and Peek published a report from the Health and Retirement Study, a longitudinal survey of a U.S. midlife cohort.¹⁴ They found that SRH

Field Code Changed

Field Code Changed

Formatted: Do not check spelling or grammar, Superscript

but not cancer. A weakness in the study was that the outcome measurement was based on self-reports. Our study supports this previous prospective research by showing an association between SRH and T2DM also when a strict verification procedure for outcome measurement is applied.

In the present study, low SRH was associated with a higher BMI which is in line with previous research. In a study investigating the relationship between self-rated health and obesity, Prosper et al. found that obese individuals had a 3-fold greater odds of reporting reduced health compared to individuals with normal weight or overweight. As obesity is also considered to be a major risk factor for diabetes ²⁹²⁸, obesity is likely to explain a substantial part of the association between low SRH and T2DM. Thus, it is not surprising that BMI may act as an important confounder in the association between SRH and T2DM in this study -or as a mediator since SRH and obesity might be on the same causal pathway.

More surprising was the fact that participants with low SRH had lower alcohol consumption and estimated reported energy intake. These findings are not easily explained and raise questions regarding the criteria for self-assessment. Previous research on occupational cohorts has suggested that SRH principally reflects physical and mental health problems and to a lesser extent age, early life factors, family history, sociodemographic variables, psychosocial factors, and health behaviours ²³²². One study that used in-depth interviews found that the same frame of reference is not used by all respondents in answering this question ³⁰²⁹. Some study participants think about specific health problems when asked to rate their health, whereas others think in terms of either general physical functioning or health behaviours. In our study, the question for SRH referred to different time frames (e.g. satisfaction withperception of health *today* in Germany and perception of health over the *last year* in Sweden). SRH has shown to be stable over time in population-based studies, suggesting that a considerable component of SRH reflects an aspect of one's enduring self-concept and to a lesser extent a

Formatted: English (U.S.), Not Expanded by / Condensed by

BMJ Open

spontaneous assessment of one's health status $\frac{3130}{4}$. Thus, the impact of different time frames on SRH assessment is likely to be small.

Previous findings suggest that there may be sex differences in the SRH-mortality association ²⁵³⁴ but we found no sex difference in the association between SRH and T2DM. SRH may also vary across countries ²⁶³⁵. In the present study, it is likely that the differences in SRH across centres to some extent can be explained by different sampling strategies and age distributions at different centres. We did not find support for heterogeneity in the association between SRH and T2DM across centres in this study. However, the study was restricted to countries in northern Europe. It is therefore not clear how these findings are generalisable to other populations. Moreover, in Heidelberg and Potsdam, the SRH question was assessed in terms of satisfaction with health and in the other centres in terms of perception of health, which may have had an influence on the distribution of responses. There were also some differences in response alternatives between centres. To some extent these differences were handled by standardization but the differences in the construct of the SRH question between centres are limitations to this study, particularly to the analysis of heterogeneity.

Strengths of the present study include the thorough ascertainment and verification of T2DM cases. Moreover, cultural differences may also have an impact on SRH, even within

Field Code Changed

```
Field Code Changed
```

BMJ Open

Europe and we included populations from four different European countries ³⁷³⁶. Several limitations of the study have already been listed, such as different <u>construct of time</u> frames for the SRH question and the restriction to countries in northern Europe. We would also like to point out that it is possible that participants reporting low SRH at baseline were more likely to seek medical advice during follow-up and hence were more likely to be tested for diabetes (detection bias). If this was the case, the study may have overestimated the risk of T2DM associated with low SRH.

In our study, part of the SRH-T2DM association seemed to be explained by medical history as well as lifestyle variables. SRH may therefore be considered as a summary health measure – also for metabolic health. If there is access to several of the established risk factors for diabetes, <u>SRHself-rated health</u> is not likely to add more than marginally to risk prediction on top of the conventional risk factors. However, whether SRH adds predictive value over and above established risk factors needs to be further analysed using adequate methods 3837.

In conclusion, results from this prospective case-cohort study provide some evidence that low self-rated health is associated with a higher risk of type 2 diabetes mellitus. The association could be only partly explained by other health-related variables, of which obesity was the strongest.

Acknowledgments

Field Code Changed

Field Code Changed

Formatted: Font: Bold

We thank all EPIC participants and staff for their contribution to the study. We thank _-- { Formatted: Font: Verdana

Footnotes

InterAct Project.

Nicola Kerrison (MRC Epidemiology Unit, Cambridge) for managing the data for the

BMJ Open

Contributors: PW had access to all data for this study, analysed the data, drafted the manuscript and is the guarantor. All authors qualify for authorship according to BMJ Open criteria. They have all contributed to conception and design, and interpretation of data, revising the article critically for important intellectual content and final approval of the version to be published.

Competing interests: All authors have completed the Unified Competing Interest form at <u>www.icmje.org/coi disclosure.pdf</u> (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisation that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Funding: Funding for the InterAct project was provided by the EU FP6 programme [grant number Integrated Project LSHM_CT_2006_037197]. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. In addition, InterAct investigators acknowledge funding from the following agencies: DLvdA and AMWS: Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); RK: Deutsche Krebshilfe.

Ethical approval: The study was approved by the IARC Institutional Review Board and by the local review boards of the participating <u>centrescenters</u>.

Data sharing: No additional data available.

Table 1 Overview of the five centres included in the study from the EPIC-InterAct study.

 Table 21
 Self-rated health by centre in 3,399 incident cases of type 2 diabetes mellitus and 4,619 participants in the subcohort in the EPIC-InterAct study. Data shown are numbers of individuals (percentage).

		Self-rated health				
Centre		Hi	gh	Lo	N	
		Excellent	Good	Moderate	Poor	
Bilthoven	Cases	13 (4.3)	184 (61.5)	73 (24.4)	29 (9.7)	
	Subcohort	52 (9.0)	403 (70.0)	101 (17.5)	21 (3.6)	
Cambridge	Cases	92 (12.3)	428 (57.1)	206 (27.5)	24 (3.2)	
	Subcohort	159 (16.2)	624 (63.4)	170 (17.4)	23 (2.3)	
Heidelberg	Cases	173 (23.1)	395 (52.8)	156 (20.9)	24 (3.2)	
	Subcohort	286 (32.9)	448 (51.5)	125 (14.4)	11 (1.3)	
Potsdam	Cases	118 (15.2)	460 (59.4)	171 (22.1)	26 (3.4)	
	Subcohort	274 (23.1)	721 (60.9)	164 (13.9)	25 (2.1)	
Umeå	Cases	155 (18.7)	369 (44.6)	236 (28.5)	67 (8.1)	
	Subcohort	265 (26.2)	477 (47.1)	215 (21.2)	55 (5.4)	

Table 32 Baseline characteristics of subcohort individuals in the EPIC-InterAct study by categories of self-rated health. Data are presented as mean and standard deviations (SD) for continuous variables and percentages and frequencies for categorical variables.


		Self-rated health									
		High				Low					
	Excell	ent	Goo	Good		Moderate		or	<i>p</i> -value for		
	Mean/%	SD/N	Mean/%	SD/N	Mean/%	SD/N	Mean/%	SD/N	overall difference [*]		
Age (years)	48.8	10.3	50.5	11.1	51.7	10.9	50.3	10.2	<0.001		
Sex (% men)	42.8	443	45.2	1208	44.8	347	37.8	51	0.24		
Educational level (%)									<0.001		
Primary school or none	19.2	194	24.4	635	37.9	287	30.8	40			
Technical/	34.6	351	35.0	910	29.6	224	32.3	42			
professional school	5 110	551	5510	510	2010		52.5				
Secondary school	14.9	151	14.2	369	14.4	109	18.5	24			
Higher (incl. university	31.3	317	26.4	688	18.1	137	18.5	24			
degree)											
BMI (kg/m²)	24.8	3.4	25.5	4.0	26.2	4.5	25.6	5.4	<0.001		
Smoking status (%)									<0.001		
Never	52.1	540	46.6	1246	41.7	323	40.7	55			
Former	27.5	285	30.1	804	30.1	233	23.7	32			
Current	18.8	195	21.0	561	26.1	202	32.6	44			
Unknown	1.5	16	2.3	62	2.2	17	3.0	4			
Physical activity (%)									< 0.001		
Inactive	15.9	160	21.3	548	31.1	231	43.3	52			
Moderately inactive	33.2	335	31.7	818	28.8	214	29.2	35			
Moderately active	25.5	257	26.8	689	21.8	162	15.0	18			
Active	25.5	257	20.2	521	18.2	135	12.5	15			
Alcohol consumption	11.5	16.2	10.8	15.2	9.2	15.4	5.6	9.8	<0.001		
(g/d)											
Total energy intake (kcal)	2016.6	649.7	2056.7	618.3	2009.4	617.3	1928.3	617.9	0.007		
Hypertension (%)	16.0	165	22.8	600	32.7	245	33.3	44	<0.001		
History of myocardial nfarction (%)	0.4	4	1.5	40	3.6	28	3.7	5	<0.001		


*Comparing excellent, good, moderate, and poor self-rated health

Table 43 Pooled hazard ratios of incident T2DM comparing low (moderate or poor) versus high (excellent or good) self-related health.

	High self-rated health	Low self-rated health
	Pooled HR (95% CI)	Pooled HR (95% CI)*
Model 1: Adjusted for age and sex	1.00 (referent)	1.67 (1.48 to 1.88)
Model 1 + education	1.00 (referent)	1.60 (1.42 to 1.81)
Model 1 + BMI	1.00 (referent)	1.38 (1.19 to 1.60)
Model 1 + smoking	1.00 (referent)	1.67 (1.48 to 1.89)
Model 1 + physical activity	1.00 (referent)	1.59 (1.41 to 1.80)
Model 1 + alcohol consumption	1.00 (referent)	1.67 (1.48 to 1.89)
Model 1 + energy intake	1.00 (referent)	1.67 (1.48 to 1.88)
Model 1 + hypertension	1.00 (referent)	1.48 (1.31 to 1.69)
Model 1 + all covariates above	1.00 (referent)	1.29 (1.09 to 1.53)

*Pooled hazard ratios calculated using a centre-stratified approach in combination with a random effects meta-analysis.





p-value for heterogeneity 0.33, I² index 13.3%

Figure 24 Centre-specific and pooled hazard ratios of incident T2DM adjusted for the variables in the final model (age, sex, education, BMI, smoking, physical activity, alcohol consumption, energy intake and hypertension).

References

<u>1.</u>	Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. National, regional, and		
	global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic		
	analysis of health examination surveys and epidemiological studies with 370 country-years		
	and 2.7 million participants. Lancet 2011;378(9785):31-40.		Formatted: Font: Italic, Do not check spelling
2.	Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and		or grammar
	2030. Diabetes Res Clin Pract 2010;87(1):4-14.		Formatted: Font: Italic, Do not check spelling
3.	Idler EL, Benyamini Y. Self-rated health and mortality: a review of twenty-seven community	-	or grammar
	studies. J. Health Soc. Behav. 1997;38(1):21-37.	·	Formatted: Font: Italic, Do not check spelling
4.	Benyamini Y. Why does self-rated health predict mortality? An update on current knowledge		or grammar
	and a research agenda for psychologists. Psychol Health 2011;26(11):1407-13.	·	Formatted: Font: Italic, Do not check spelling
5.	Halford C, Anderzen I, Arnetz B. Endocrine measures of stress and self-rated health: a	-	or grammar
	longitudinal study. J Psychosom Res 2003;55(4):317-20.		Formatted: Font: Italic, Do not check spelling
6.	DeSalvo KB, Bloser N, Reynolds K, He J, Muntner P. Mortality prediction with a single general	-	or grammar
	self-rated health question. A meta-analysis. J Gen Intern Med 2006;21(3):267-75.		Formatted: Font: Italic, Do not check spelling
7.	Mavaddat N, Kinmonth AL, Sanderson S, Surtees P, Bingham S, Khaw KT. What determines	-	or grammar
	Self-Rated Health (SRH)? A cross-sectional study of SF-36 health domains in the EPIC-Norfolk		
	cohort. J Epidemiol Community Health 2011;65(9):800-6.		Formatted: Font: Italic, Do not check spelling
8.	DeSalvo KB, Jones TM, Peabody J, McDonald J, Fihn S, Fan V, et al. Health care expenditure	-	or grammar
	prediction with a single item, self-rated health measure. Med Care 2009;47(4):440-7.		Formatted: Font: Italic, Do not check spelling
9.	Ramkumar A, Quah JL, Wong T, Yeo LS, Nieh CC, Shankar A, et al. Self-rated health,	-	or grammar
	associated factors and diseases: a community-based cross-sectional study of Singaporean		
	adults aged 40 years and above. Ann. Acad. Med. Singapore 2009;38(7):606-7.	1.	Formatted: Font: Italic, Do not check spelling
10.	Shadbolt B. Some correlates of self-rated health for Australian women. Am J Public Health	_	or grammar
	1997;87(6):951-6.		Formatted: Font: Italic, Do not check spelling
11.	Manor O, Matthews S, Power C. Self-rated health and limiting longstanding illness: inter-		or grammar
	relationships with morbidity in early adulthood. Int J Epidemiol 2001;30(3):600-7.	1.1	Formatted: Font: Italic, Do not check spelling
12.	Leosdottir M, Willenheimer R, Persson M, Nilsson PM. The association between	_	or grammar
	glucometabolic disturbances, traditional cardiovascular risk factors and self-rated health by		
	age and gender: a cross-sectional analysis within the Malmo Preventive Project. Cardiovasc		Formatted: Font: Italic, Do not check spelling
	Diabetol 2011;10:118.		or grammar
13.	Tapp RJ, O'Neil A, Shaw JE, Zimmet PZ, Oldenburg BF. Is there a link between components of		
	health-related functioning and incident impaired glucose metabolism and type 2 diabetes?		
	The Australian Diabetes Obesity and Lifestyle (AusDiab) study. Diabetes Care 2010;33(4):757-	·	Formatted: Font: Italic, Do not check spelling
	<u>62.</u>		or grammar
<u>14</u> .	Latham K, Peek CW. Self-rated health and morbidity onset among late midlife u.s. Adults. J.		Formatted: Font: Italic, Do not check spelling
	Gerontol. B. Psychol. Sci. Soc. Sci. 2013;68(1):107-16.		or grammar
<u>15.</u>	Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, et al. European Prospective		
	Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public		Formatted: Font: Italic, Do not check spelling
	Health Nutr 2002;5(6B):1113-24.		or grammar
16.	Langenberg C, Sharp S, Forouhi NG, Franks PW, Schulze MB, Kerrison N, et al. Design and		
	cohort description of the InterAct Project: an examination of the interaction of genetic and		
	lifestyle factors on the incidence of type 2 diabetes in the EPIC Study. Diabetologia		Formatted: Font: Italic, Do not check spelling
	2011;54(9):2272-82.		or grammar
17.	Walker JD, Maxwell CJ, Hogan DB, Ebly EM. Does self-rated health predict survival in older		
	persons with cognitive impairment? J. Am. Geriatr. Soc. 2004;52(11):1895-900.	·	Formatted: Font: Italic, Do not check spelling
<u>18</u> .	McEwen LN, Kim C, Haan MN, Ghosh D, Lantz PM, Thompson TJ, et al. Are health-related		or grammar
	guality-of-life and self-rated health associated with mortality? Insights from Translating		
	Research Into Action for Diabetes (TRIAD). Prim Care Diabetes 2009;3(1):37-42.		Formatted: Font: Italic, Do not check spelling
•			or grammar

BMJ Open

1
ว
2
3
4
5
6
7
1
8
9
10
11
10
12
13
14
15
16
17
17
18
19
$\begin{array}{c} 2\\ 2\\ 3\\ 4\\ 5\\ 6\\ 7\\ 8\\ 9\\ 10\\ 11\\ 23\\ 14\\ 15\\ 16\\ 17\\ 18\\ 19\\ 20\\ 22\\ 23\\ 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 03\\ 12\\ 23\\ 34\\ 35\\ 36\\ 37\\ 82\\ 20\\ 10\\ 12\\ 23\\ 24\\ 56\\ 27\\ 28\\ 29\\ 03\\ 12\\ 23\\ 34\\ 35\\ 36\\ 37\\ 82\\ 20\\ 20\\ 20\\ 20\\ 20\\ 20\\ 20\\ 20\\ 20\\ 2$
21
22
22
23
24
25
26
20
21
28
29
30
21
20
32
33
34
35
36
07
31
38
39
40
41
42
42
43
44
45
46
47
48
49
50
51
52
52
53
54
55
56
57
58
59
60

	relationship between self-rated health and mortality in older black and white Americans. J.		Formatted: Font: Italic, Do not check spelling
	Am. Geriatr. Soc. 2007;55(10):1624-9.	_	or grammar
20.	Pischon T, Boeing H, Hoffmann K, Bergmann M, Schulze MB, Overvad K, et al. General and		
	abdominal adiposity and risk of death in Europe. <u>N Engl J Med 2008;359(20):2105-20.</u>		Formatted: Font: Italic, Do not check spelling
21.	Validity of a short questionnaire to assess physical activity in 10 European countries. Eur J		or grammar
	Epidemiol 2012;27(1):15-25.		Formatted: Font: Italic, Do not check spellin
22.	Barlow WE, Ichikawa L, Rosner D, Izumi S. Analysis of case-cohort designs. J Clin Epidemiol		or grammar
	<u>1999;52(12):1165-72.</u>		Formatted: Font: Italic, Do not check spellin or grammar
23.	Singh-Manoux A, Martikainen P, Ferrie J, Zins M, Marmot M, Goldberg M. What does self		or grannia
	rated health measure? Results from the British Whitehall II and French Gazel cohort studies.		
	J. Epidemiol. Community Health 2006;60(4):364-72.	·	Formatted: Font: Italic, Do not check spellin
24.	Kenward MG, Carpenter J. Multiple imputation: current perspectives. <u>Stat. Methods Med.</u>		or grammar
	<u>Res. 2007;16(3):199-218.</u>		Formatted: Font: Italic, Do not check spellin
25.	Benjamins MR, Hummer RA, Eberstein IW, Nam CB. Self-reported health and adult mortality		or grammar
	risk: an analysis of cause-specific mortality. <u>Soc Sci Med 2004;59(6):1297-306.</u>	`	Formatted: Font: Italic, Do not check spellir
	Wennberg P, Rolandsson O, Jerden L, Boeing H, Sluik D, Kaaks R, et al. Self-rated health and		or grammar
	mortality in individuals with diabetes mellitus: prospective cohort study. <u>BMJ Open</u>	^	Formatted: Font: Italic, Do not check spellir
	<u>2012;2(1):e000760.</u>		or grammar
27.	Dasbach EJ, Klein R, Klein BE, Moss SE. Self-rated health and mortality in people with		
	diabetes. <u>Am J Public Health 1994;84(11):1775-9.</u>	`	Formatted: Font: Italic, Do not check spelling
28.	Prosper MH, Moczulski VL, Qureshi A. Obesity as a predictor of self-rated health. <u>Am J Health</u>		or grammar
	<u>Behav 2009;33(3):319-29.</u>		Formatted: Font: Italic, Do not check spelli
29.	Haffner SM. Relationship of metabolic risk factors and development of cardiovascular disease		or grammar
	and diabetes. <u>Obesity (Silver Spring)</u> 2006;14 Suppl 3:121S-27S.	`	Formatted: Font: Italic, Do not check spelli
30.	Krause NM, Jay GM. What do global self-rated health items measure? <u>Med Care</u>		or grammar
	<u>1994;32(9):930-42.</u>		Formatted: Font: Italic, Do not check spellir
31.	Bailis DS, Segall A, Chipperfield JG. Two views of self-rated general health status. <u>Soc. Sci.</u>		or grammar
	<u>Med. 2003;56(2):203-17.</u>		Formatted: Font: Italic, Do not check spellir or grammar
32.	Gregg EW, Gu Q, Cheng YJ, Narayan KM, Cowie CC. Mortality trends in men and women with		or graninal
	diabetes, 1971 to 2000. Ann. Intern. Med. 2007;147(3):149-55.	·	Formatted: Font: Italic, Do not check spelling
33.	Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer		or grammar
	<u>2009;16(4):1103-23.</u>		Formatted: Font: Italic, Do not check spelli
34.	Layes A, Asada Y, Kepart G. Whiners and deniers - What does self-rated health measure? <u>Soc.</u>		or grammar
	<u>Sci. Med. 2011.</u>		Formatted: Font: Italic, Do not check spellin or grammar
35.	Benyamini Y, Blumstein T, Lusky A, Modan B. Gender differences in the self-rated health-		or grannar
	mortality association: is it poor self-rated health that predicts mortality or excellent self-		
	rated health that predicts survival? <i>Gerontologist</i> 2003;43(3):396-405; discussion 372-5.	·	Formatted: Font: Italic, Do not check spelli
36.	Vadla D, Bozikov J, Akerstrom B, Cheung WY, Kovacic L, Masanovic M, et al. Differences in		or grammar
	healthcare service utilisation in elderly, registered in eight districts of five European		
	countries. <u>Scand J Public Health 2011;39(3):272-9.</u>	·	Formatted: Font: Italic, Do not check spelli
37.	Jylha M, Guralnik JM, Ferrucci L, Jokela J, Heikkinen E. Is self-rated health comparable across		or grammar
	cultures and genders? J. Gerontol. B. Psychol. Sci. Soc. Sci. 1998;53(3):S144-52.	·	Formatted: Font: Italic, Do not check spelli
38.	Pencina MJ, D'Agostino RB, Sr., D'Agostino RB, Jr., Vasan RS. Evaluating the added predictive		or grammar
	ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat.		Formatted: Font: Italic, Do not check spellin
	Med. 2008;27(2):157-72; discussion 207-12.		or grammar
	ب		Formatted: Indent: Left: 0", Hanging: 0.5
1.	Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. National, regional, and		Space After: 0 pt, Line spacing: single
	global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic		
	analysis of health examination surveys and epidemiological studies with 370 country-years		

1	
2 3 4 5 6 7 8	
3	
4	
5	
6	
7	
1	
8	
9	
10	
11	
10	
12	
13	
14	
15	
16	
47	
17	
18	
19	
9 10 11 12 13 14 15 16 17 18 20 21 22 23 24 25 27 28 29 31 32 33 34 35 36 37 38 40	
21	
∠ I 00	
22	
23	
24	
25	
20	
20	
27	
28	
29	
30	
04	
31	
32	
33	
34	
25	
30	
36	
37	
38	
30	
40	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
49 50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
09	
60	

2.	Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and
۷.	2030. Diabetes Res Clin Pract 2010;87(1):4-14.
3.	Idler EL, Benyamini Y. Self rated health and mortality: a review of twenty seven community
	studies. J. Health Soc. Behav. 1997;38(1):21-37.
	Benyamini Y. Why does self-rated health predict mortality? An update on current knowledge
1.	
_	and a research agenda for psychologists. Psychol Health 2011;26(11):1407-13.
	Halford C, Anderzen I, Arnetz B. Endocrine measures of stress and self-rated health: a
	longitudinal study. J Psychosom Res 2003;55(4):317-20.
.	DeSalvo KB, Bloser N, Reynolds K, He J, Muntner P. Mortality prediction with a single general
	self-rated health question. A meta-analysis. J Gen Intern Med 2006;21(3):267-75.
7	Mavaddat N, Kinmonth AL, Sanderson S, Surtees P, Bingham S, Khaw KT. What determines
	Self-Rated Health (SRH)? A cross-sectional study of SF-36 health domains in the EPIC-Norfolk
	cohort. J Epidemiol Community Health 2011;65(9):800-6.
3.	- DeSalvo KB, Jones TM, Peabody J, McDonald J, Fihn S, Fan V, et al. Health care expenditure
	prediction with a single item, self-rated health measure. <i>Med Care</i> 2009;47(4):440-7.
)	Ramkumar A, Quah JL, Wong T, Yeo LS, Nieh CC, Shankar A, et al. Self-rated health,
	associated factors and diseases: a community-based cross-sectional study of Singaporean
	adults aged 40 years and above. Ann. Acad. Med. Singapore 2009;38(7):606-7.
10.	Shadbolt B. Some correlates of self rated health for Australian women. Am J Public Health
	1997;87(6):951 6.
11.	Manor O, Matthews S, Power C. Self rated health and limiting longstanding illness: inter-
	relationships with morbidity in early adulthood. Int J Epidemiol 2001;30(3):600-7.
2.	Leosdottir M, Willenheimer R, Persson M, Nilsson PM. The association between
.2.	glucometabolic disturbances, traditional cardiovascular risk factors and self-rated health by
	age and gender: a cross sectional analysis within the Malmo Preventive Project. Cardiovasc
12	Diabetol 2011;10:118.
13.	Tapp RJ, O'Neil A, Shaw JE, Zimmet PZ, Oldenburg BF. Is there a link between components of
	health-related functioning and incident impaired glucose metabolism and type 2 diabetes?
	The Australian Diabetes Obesity and Lifestyle (AusDiab) study. <i>Diabetes Care</i> 2010;33(4):757-
	62.
14.	Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, et al. European Prospective
	Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public
	Health Nutr 2002;5(6B):1113-24.
15.	
	cohort description of the InterAct Project: an examination of the interaction of genetic and
	lifestyle factors on the incidence of type 2 diabetes in the EPIC Study. Diabetologia
	2011;54(9):2272-82.
16.	Walker JD, Maxwell CJ, Hogan DB, Ebly EM. Does self-rated health predict survival in older
	persons with cognitive impairment? J. Am. Geriatr. Soc. 2004;52(11):1895-900.
17.	
	quality-of-life and self-rated health associated with mortality? Insights from Translating
	Research Into Action for Diabetes (TRIAD). Prim Care Diabetes 2009;3(1):37-42.
18.	Lee SJ, Moody-Ayers SY, Landefeld CS, Walter LC, Lindquist K, Segal MR, et al. The
	relationship between self-rated health and mortality in older black and white Americans. J.
	Am. Geriatr. Soc. 2007;55(10):1624-9.
19.	Pischon T, Boeing H, Hoffmann K, Bergmann M, Schulze MB, Overvad K, et al. General and
	abdominal adiposity and risk of death in Europe. N Engl J Med 2008;359(20):2105-20.
<u>20.</u>	Validity of a short questionnaire to assess physical activity in 10 European countries. Eur J
-0.	Epidemiol 2012;27(1):15-25.
11	
21.	Barlow WE, Ichikawa L, Rosner D, Izumi S. Analysis of case-cohort designs. J Clin Epidemiol
	1999;52(12):1165-72.

BMJ Open

2
2
3
4
5
5
6
7
<u>'</u>
8
9
40
10
11
10
12
13
1/
14
15
16
47
17
18
10
19
20
21
~ 1
22
23
24
25
26
20
27
28
20
29
30
00
'21
51
32
32
32 33
32 33 34
32 33 34 35
32 33 34 35
32 33 34 35 36
32 33 34 35 36 37
32 33 34 35 36 37
32 33 34 35 36 37 38
32 33 34 35 36 37 38 39
$2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 1 \\ 1 \\ 1 \\ 2 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1$
40
40 41
40 41
40 41 42
40 41 42 43
40 41 42 43
40 41 42 43 44
40 41 42 43 44 45
40 41 42 43 44 45 46
40 41 42 43 44 45 46
40 41 42 43 44 45 46 47
40 41 42 43 44 45 46 47 48
40 41 42 43 44 45 46 47 48
40 41 42 43 44 45 46 47 48 49
40 41 42 43 44 45 46 47 48 49 50
40 41 42 43 44 45 46 47 48 49 50
40 41 42 43 44 45 46 47 48 49 50 51
40 41 42 43 44 45 46 47 48 49 50 51 52
40 41 42 43 44 45 46 47 48 49 50 51
40 41 42 43 44 45 46 47 48 49 50 51 52 53
40 41 42 43 44 45 46 47 48 49 50 51 52 53 54
40 41 42 43 44 45 46 47 48 95 51 52 53 55
40 41 42 43 44 45 46 47 48 95 51 52 53 55
40 41 42 43 44 45 46 47 49 50 51 52 53 45 55 56
40 41 42 43 44 45 46 47 49 55 55 55 55 55 57
40 41 42 43 44 45 46 47 49 55 55 55 55 55 57
40 41 42 43 44 54 47 48 90 51 52 53 55 57 58
40 41 42 43 44 45 46 47 49 55 55 55 55 55 57

22.	Singh-Manoux A, Martikainen P, Ferrie J, Zins M, Marmot M, Goldberg M. What does self
	rated health measure? Results from the British Whitehall II and French Gazel cohort studies.
	J. Epidemiol. Community Health 2006;60(4):364 72.
23.	Kenward MG, Carpenter J. Multiple imputation: current perspectives. Stat. Methods Med.
	Res. 2007;16(3):199-218.
24.	Benjamins MR, Hummer RA, Eberstein IW, Nam CB. Self-reported health and adult mortality
	risk: an analysis of cause-specific mortality. Soc Sci Med 2004;59(6):1297-306.
25.	Wennberg P, Rolandsson O, Jerden L, Boeing H, Sluik D, Kaaks R, et al. Self rated health and
	mortality in individuals with diabetes mellitus: prospective cohort study. BMJ Open
	2012;2(1):e000760.
<u>26.</u>	Dasbach EJ, Klein R, Klein BE, Moss SE. Self-rated health and mortality in people with
	diabetes. Am J Public Health 1994;84(11):1775-9.
27.	- Prosper MH, Moczulski VL, Qureshi A. Obesity as a predictor of self-rated health. Am J Health
	Behav 2009;33(3):319-29.
28.	- Haffner SM. Relationship of metabolic risk factors and development of cardiovascular diseas
	and diabetes. Obesity (Silver Spring) 2006;14 Suppl 3:121S-27S.
<u> 29.</u>	Krause NM, Jay GM. What do global self-rated health items measure? Med Care
	1994;32(9):930-42.
30	Bailis DS, Segall A, Chipperfield JG. Two views of self rated general health status. Soc. Sci.
	Med. 2003;56(2):203 17.
31.	- Gregg EW, Gu Q, Cheng YJ, Narayan KM, Cowie CC. Mortality trends in men and women with
	diabetes, 1971 to 2000. Ann. Intern. Med. 2007;147(3):149-55.
32.	- Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer
	2009;16(4):1103-23.
33.	- Layes A, Asada Y, Kepart G. Whiners and deniers - What does self rated health measure? Soc
	Sci. Med. 2011.
34.	Benyamini Y, Blumstein T, Lusky A, Modan B. Gender differences in the self-rated health-
	mortality association: is it poor self-rated health that predicts mortality or excellent self-
	rated health that predicts survival? Gerontologist 2003;43(3):396-405; discussion 372-5.
35.	- Vadla D, Bozikov J, Akerstrom B, Cheung WY, Kovacic L, Masanovic M, et al. Differences in
	healthcare service utilisation in elderly, registered in eight districts of five European
	countries. Scand J Public Health 2011;39(3):272 9.
36 .	- Jylha M, Guralnik JM, Ferrucci L, Jokela J, Heikkinen E. Is self-rated health comparable across
	cultures and genders? J. Gerontol. B. Psychol. Sci. Soc. Sci. 1998;53(3):S144-52.
37.	Pencina MJ, D'Agostino RB, Sr., D'Agostino RB, Jr., Vasan RS. Evaluating the added predictive
	ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat.
	Med. 2008;27(2):157-72; discussion 207-12.

Appendix

All questionnaires were standardized to fit the question (with four response alternatives):

How satisfied are you today with your health?

1 Excellent

2
2
3
4
5
~
6
7
8
9
10
10
11
12
12
13
14
45
15
16
17
17
18
10
19
20
$\begin{array}{c} 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 11 \\ 2 \\ 11 \\ 13 \\ 14 \\ 15 \\ 16 \\ 17 \\ 18 \\ 19 \\ 21 \\ 22 \\ 22 \\ 24 \\ 25 \\ 27 \\ 28 \\ 9 \\ 30 \\ 13 \\ 23 \\ 34 \\ 35 \\ 36 \\ 78 \\ 9 \\ 20 \\ 21 \\ 22 \\ 22 \\ 24 \\ 25 \\ 27 \\ 28 \\ 9 \\ 30 \\ 13 \\ 23 \\ 34 \\ 35 \\ 36 \\ 78 \\ 9 \\ 20 \\ 21 \\ 22 \\ 22 \\ 24 \\ 25 \\ 27 \\ 28 \\ 9 \\ 30 \\ 11 \\ 23 \\ 33 \\ 34 \\ 35 \\ 36 \\ 78 \\ 9 \\ 20 \\ 21 \\ 22 \\ 22 \\ 24 \\ 25 \\ 27 \\ 28 \\ 9 \\ 30 \\ 11 \\ 23 \\ 34 \\ 35 \\ 36 \\ 78 \\ 39 \\ 20 \\ 20 \\ 20 \\ 20 \\ 20 \\ 20 \\ 20 \\ 2$
<u> </u>
22
23
20
24
25
~~~
26
27
20
28
29
20
30
31
32
52
33
34
07
35
36
07
37
38
20
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

2	Good	

- 3 Moderate
- 4 Poor

Description of the original questions and how they were standardized:

Bilthoven 1993-94

Question: What do you think about your health in general?

Response alternatives	Standardized
1 Excellent	1 Excellent
2 Good	2 Good
3 Reasonable	3 Moderate
4 Mediocre	4 Poor
5 Poor	4 Poor
9 More than 1 option indicated	Missing value

# Bilthoven 1995-97

Question: What do you think about your health in general?

Response alternatives	Standardized
1 Excellent	1 Excellent
2 Very good	2 Good
3 Good	2 Good
4 Reasonable	3 Moderate
5 Mediocre	4 Poor
9 More than 1 option indicated	Missing value
Cambridge	
Question: How would you rate you	anneral health?

### Cambridge

Question: How would you rate your general health?

Response alternatives	Standardized	
1 Excellent	1 Excellent	
2 Good	2 Good	
3 Moderate	3 Moderate	
4 Poor	4 Poor	

#### Heidelberg

Question: On the whole, how satisfied are you today with your health?

Response alternatives	Standardized
1 Very satisfied	1 Excellent
2 More satisfied	2 Good
3 More dissatisfied	3 Moderate
4 Very dissatisfied	4 Poor
8 Do not know	Missing value

Potsdam

Question: On the whole, how satisfied are you today with your health?

Response alternatives	Standardized	
1 Very satisfied	1 Excellent	
2 More likely satisfied	2 Good	
3 More likely dissatisfied	3 Moderate	
4 Very dissatisfied	4 Poor	
8 Do not know	Missing value	

Umeå

Question: How do you judge that your state of health has been in the last year?

Response alternatives	Standardized
1 Very well	1 Excellent
2 Quiet well	2 Good
3 Fairly well	3 Moderate
4 Quiet bad	4 Poor
5 Bad	4 Poor
9 Inconsistent answer	Missing value

Image: file and abstract         1         (a) Indicate the study's design with a commonly used term in the title or the abstraat (b) Provide in the abstract an informative and balanced summary of what was done and what was found           introduction         3         State specific objectives, including any prespecified hypotheses           Methods         2         Explain the scientific background and rationale for the investigation being reported           Describe the setting, locations, and relevant dates, including periods of recruitment exposure, follow-up, and data collection         9           Participants         6         (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe the deligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls           Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants         (b) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants           (b) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants         (c) Cohort study—Give the eligibility criteria, and the sources and methods of exposed and unexposed           Case-control study—For matched studies, give matching criteria and the number or controls per case         (b) Cohort study—For matched studies, give matching criteria and the number or controls per case           Variables         7         Clearly define all outcomes, exposures, predictors, potential co		Item No	Recommendation
and what was found           introduction         2           Background/rationale         2           Explain the scientific background and rationale for the investigation being reported           Objectives         3           State specific objectives, including any prespecified hypotheses           Methods           Study design         4           Present key elements of study design carly in the paper           Study design         5           Describe the setting, locations, and relevant dates, including periods of recruitment exposure, follow-up, and data collection           Participants         6           (a) Cohort study—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls           Cross-sectional study—Give the eligibility criteria, and the sources and methods of exposed and unexposed           Cross-sectional study—For matched studies, give matching criteria and the number of exposed and unexposed           Case-control study—For matched studies, give matching criteria and the number of assessment (measurement). Describe comparability of assessment methods of assessment methods of assessment methods of metast. Give diagnostic criteria, if applicable           Data sources/         8*           For each variable of interest, give sources of bias           Study size         10           Explain how the study size w	Title and abstract		(a) Indicate the study's design with a commonly used term in the title or the abstract
Introduction         Explain the scientific background and rationale for the investigation being reported           Dispectives         3         State specific objectives, including any prespecified hypotheses           Methods			(b) Provide in the abstract an informative and balanced summary of what was done
Background/rationale       2       Explain the scientific background and rationale for the investigation being reported         Dijectives       3       State specific objectives, including any prespecified hypotheses         Wethods			•
Background/rationale       2       Explain the scientific background and rationale for the investigation being reported         Dijectives       3       State specific objectives, including any prespecified hypotheses         Wethods	Introduction		
Dijectives       3       State specific objectives, including any prespecified hypotheses         Methods       5       Describe the setting, locations, and relevant dates, including periods of recruitment exposure, follow-up, and data collection         Participants       6       (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up         Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls         Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants         (b) Cohort study—For matched studies, give matching criteria and the number of exposed and unexposed         Case-control study—For matched studies, give matching criteria and the number of exposed and unexposed         Variables       7         Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable         Pata sources/       8*         For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group         Bias       9       Describe any efforts to address potential sources of bias         Study size       10       Explain how the study size was arrived at         Quantitative variables       11       Explain ho		2	Explain the scientific background and rationale for the investigation being reported
Wethods         Image: Control and the problem of	-		
Study design       4       Present key elements of study design early in the paper         Setting       5       Describe the setting, locations, and relevant dates, including periods of recruitment exposure, follow-up, and data collection         Participants       6       (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up         Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls         Cross-sectional study—Give the eligibility criteria, and the sources and methods of exposed and unexposed         (b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed         Case-control study—For matched studies, give matching criteria and the number or controls per case         Variables       7       Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable         Study size       10       Explain how the study size was arrived at         Quantitative variables       11       Explain how the study size was arrived at         Quantitative variables       12       (a) Describe any ethods used to examine subgroups and interactions         (c) Explain how the study size was arrived at       (c) Explain how missing data were addressed         (d) Describe any methods used to examine subgroups and interactions       (c)	•	5	State specifie objectives, merading any prespective hypotheses
Setting       5       Describe the setting, locations, and relevant dates, including periods of recruitment exposure, follow-up, and data collection         Participants       6       (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up         Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls         Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants         (b) Cohort study—Give the eligibility criteria, and the sources and methods of exposed and unexposed         Cross-sectional study—For matched studies, give matching criteria and number of exposed and unexposed         Variables       7         Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable         Data sources/       8*         neasurement       assessment (measurement). Describe comparability of assessment methods if there is more than one group         Bias       9       Describe any efforts to address potential sources of bias         Study size       10       Explain how the study size was arrived at         Quantitative variables       11       Explain how the study—If applicable were handled in the analyses. If applicable, describe which groupings were chosen and why         (d) Describe any methods used to examine sub		1	Present key alaments of study design early in the paper
exposure, follow-up, and data collection           Participants         6         (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls           Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants         (b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed           Case-control study—For matched studies, give matching criteria and the number o controls per case         7           Variables         7         Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable           Data sources/         8*         For each variable of interest, give sources of bias           Study size         10         Explain how the study size was arrived at           Quantitative variables         11         Explain how the study size was arrived at           Quantitative variables         12         (a) Describe any methods used to examine subgroups and interactions           (c) Explain how missing data were addressed         (d) Cohort study—If applicable, explain how matching of cases and controls was addressed           (d) Cohort study—If applicable, explain how matching of cases and controls was addressed         (c) Cohort study—If applicable, explain how matching of	· ·		
selection of participants. Describe methods of follow-up       Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls         Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants       (b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed         Case-control study—For matched studies, give matching criteria and the number of exposed and unexposed       Case-control study—For matched studies, give matching criteria and the number of exposed and unexposed         Variables       7       Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable         Data sources/       8*       For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group         Bias       9       Describe any efforts to address potential sources of bias         Study size       10       Explain how the study size was arrived at         Quantitative variables       11       Explain how quantitative variables were handled in the analyses. If applicable, describe any methods used to control for confounding (b) Describe any methods used to examine subgroups and interactions         (c) Explain how missing data were addressed       Case-control study—If applicable, explain how matching of cases and controls was addressed         (d) Cohort study—If	Setting	0	
Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls         Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants         (b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed         Case-control study—For matched studies, give matching criteria and the number of controls per case         Variables       7         Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable         Oata sources/       8*         For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group         Bias       9         Describe any efforts to address potential sources of bias         Study size       10         Explain how the study size was arrived at         Quantitative variables       11         Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why         Statistical methods       12         (a) Describe any methods used to examine subgroups and interactions         (c) Cohort study—If applicable, explain how matching of cases and controls wataddressed         (d) Cohort study—If applicable, explain how matching of cases an	Participants	6	(a) Cohort study—Give the eligibility criteria, and the sources and methods of
case ascertainment and control selection. Give the rationale for the choice of cases and controls         Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants         (b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed         Case-control study—For matched studies, give matching criteria and the number or controls per case         Variables       7         Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable         Data sources/       8*         For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group         Bias       9         Describe any efforts to address potential sources of bias         Study size       10         Explain how the study size was arrived at         Quantitative variables       11         Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why         Statistical methods       12         (a) Describe any methods used to examine subgroups and interactions         (c) Explain how missing data were addressed         (d) Cohort study—If applicable, explain how matching of cases and controls was addressed         (c) Explain how missing data were addressed <tr< td=""><td></td><td></td><td>selection of participants. Describe methods of follow-up</td></tr<>			selection of participants. Describe methods of follow-up
and controls         Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants         (b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed         Case-control study—For matched studies, give matching criteria and the number of controls per case         Variables       7         Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable         Data sources/       8*         For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group         Bias       9         Describe any efforts to address potential sources of bias         Study size       10         Explain how the study size was arrived at         Quantitative variables       11         Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why         Statistical methods       12         (a) Describe any methods used to examine subgroups and interactions         (c) Explain how missing data were addressed         (d) Cohort study—If applicable, explain how matching of cases and controls was addressed         Case-control study—If applicable, describe analytical methods taking account o sampling strategy         (g) Describe any sen			Case-control study—Give the eligibility criteria, and the sources and methods of
Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants         (b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed         Case-control study—For matched studies, give matching criteria and the number of controls per case         Variables       7         Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable         Data sources/       8*         For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group         Bias       9         Describe any efforts to address potential sources of bias         Study size       10         Explain how the study variables were handled in the analyses. If applicable, describe which groupings were chosen and why         Statistical methods       12         (a) Describe any methods used to examine subgroups and interactions         (c) Explain how missing data were addressed         (d) Cohort study—If applicable, explain how matching of cases and controls was addressed         (d) Cohort study—If applicable, explain how matching of cases and controls was addressed         (c) Explain how missing data were addressed         (c) Describe any sensitivity analyses			case ascertainment and control selection. Give the rationale for the choice of cases
selection of participants         (b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed         Case-control study—For matched studies, give matching criteria and the number of controls per case         Variables       7         Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable         Data sources/       8*         For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group         Bias       9         Describe any efforts to address potential sources of bias         Study size       10         Explain how the study size was arrived at         Quantitative variables       11         Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why         Statistical methods       12         (a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions         (c) Explain how missing data were addressed       (d) Cohort study—If applicable, explain how matching of cases and controls was addressed         (a) Cohort study—If applicable, explain how matching of cases and controls was addressed       (g) Describe any sensitivity analyses			and controls
selection of participants         (b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed         Case-control study—For matched studies, give matching criteria and the number of controls per case         Variables       7         Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable         Data sources/       8*         For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group         Bias       9         Describe any efforts to address potential sources of bias         Study size       10         Explain how the study size was arrived at         Quantitative variables       11         Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why         Statistical methods       12         (a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions         (c) Explain how missing data were addressed       (d) Cohort study—If applicable, explain how matching of cases and controls was addressed         (a) Cohort study—If applicable, explain how matching of cases and controls was addressed       (g) Describe any sensitivity analyses			Cross-sectional study—Give the eligibility criteria, and the sources and methods of
exposed and unexposed       Case-control study—For matched studies, give matching criteria and the number of controls per case         Variables       7       Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable         Data sources/       8*       For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group         Bias       9       Describe any efforts to address potential sources of bias         Study size       10       Explain how the study size was arrived at         Quantitative variables       11       Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why         Statistical methods       12       (a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions         (c) Explain how missing data were addressed       (d) Cohort study—If applicable, explain how matching of cases and controls was addressed         (d) Cohort study—If applicable, describe analytical methods taking account o sampling strategy       (g) Describe any sensitivity analyses			
Case-control study—For matched studies, give matching criteria and the number of controls per case         Variables       7       Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable         Data sources/       8*       For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group         Bias       9       Describe any efforts to address potential sources of bias         Study size       10       Explain how the study size was arrived at         Quantitative variables       11       Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why         Statistical methods       12       (a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions         (c) Explain how missing data were addressed       (d) Cohort study—If applicable, explain how matching of cases and controls was addressed         Cross-sectional study—If applicable, describe analytical methods taking account o sampling strategy       (g) Describe any sensitivity analyses			(b) Cohort study—For matched studies, give matching criteria and number of
controls per case           Variables         7         Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable           Data sources/         8*         For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group           Bias         9         Describe any efforts to address potential sources of bias           Study size         10         Explain how the study size was arrived at           Quantitative variables         11         Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why           Statistical methods         12         (a) Describe any methods used to examine subgroups and interactions           (c) Explain how missing data were addressed         (d) Cohort study—If applicable, explain how matching of cases and controls was addressed           Cross-sectional study         If applicable, describe analytical methods taking account o sampling strategy           (g) Describe any sensitivity analyses			exposed and unexposed
Variables       7       Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable         Data sources/       8*       For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group         Bias       9       Describe any efforts to address potential sources of bias         Study size       10       Explain how the study size was arrived at         Quantitative variables       11       Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why         Statistical methods       12       (a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions         (c) Explain how missing data were addressed       (d) Cohort study—If applicable, explain how matching of cases and controls was addressed         (d) Cohort study—If applicable, explain how matching of cases and controls was addressed       Cross-sectional study—If applicable, describe analytical methods taking account o sampling strategy         (c) Describe any sensitivity analyses       (c) Describe any sensitivity analyses			Case-control study-For matched studies, give matching criteria and the number of
modifiers. Give diagnostic criteria, if applicable         Data sources/       8*         For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group         Bias       9         Describe any efforts to address potential sources of bias         Study size       10         Explain how the study size was arrived at         Quantitative variables       11         Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why         Statistical methods       12         (a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions         (c) Explain how missing data were addressed         (d) Cohort study—If applicable, explain how matching of cases and controls was addressed         Cross-sectional study—If applicable, describe analytical methods taking account o sampling strategy         (e) Describe any sensitivity analyses			controls per case
Data sources/       8*       For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group         Bias       9       Describe any efforts to address potential sources of bias         Study size       10       Explain how the study size was arrived at         Quantitative variables       11       Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why         Statistical methods       12       (a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions         (c) Explain how missing data were addressed       (d) Cohort study—If applicable, explain how matching of cases and controls was addressed         (d) Cohort study—If applicable, describe analytical methods taking account o sampling strategy       (g) Describe any sensitivity analyses	Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect
measurement       assessment (measurement). Describe comparability of assessment methods if there is more than one group         Bias       9       Describe any efforts to address potential sources of bias         Study size       10       Explain how the study size was arrived at         Quantitative variables       11       Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why         Statistical methods       12       (a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions         (c) Explain how missing data were addressed       (d) Cohort study—If applicable, explain how loss to follow-up was addressed         (d) Cohort study—If applicable, explain how matching of cases and controls was addressed       cross-sectional study—If applicable, describe analytical methods taking account o sampling strategy         (g) Describe any sensitivity analyses       (g) Describe any sensitivity analyses			modifiers. Give diagnostic criteria, if applicable
is more than one group         Bias       9         Describe any efforts to address potential sources of bias         Study size       10         Explain how the study size was arrived at         Quantitative variables       11         Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why         Statistical methods       12         (a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions         (c) Explain how missing data were addressed         (d) Cohort study—If applicable, explain how loss to follow-up was addressed         Cross-sectional study—If applicable, explain how matching of cases and controls was addressed         Cross-sectional study—If applicable, describe analytical methods taking account o sampling strategy         (g) Describe any sensitivity analyses	Data sources/	8*	For each variable of interest, give sources of data and details of methods of
Bias       9       Describe any efforts to address potential sources of bias         Study size       10       Explain how the study size was arrived at         Quantitative variables       11       Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why         Statistical methods       12       (a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions         (c) Explain how missing data were addressed       (d) Cohort study—If applicable, explain how loss to follow-up was addressed         (d) Cohort study—If applicable, explain how matching of cases and controls was addressed       Cross-sectional study—If applicable, describe analytical methods taking account o sampling strategy         (e) Describe any sensitivity analyses       (d) Describe any sensitivity analyses	measurement		assessment (measurement). Describe comparability of assessment methods if there
Study size       10       Explain how the study size was arrived at         Quantitative variables       11       Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why         Statistical methods       12       (a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions         (c) Explain how missing data were addressed       (d) Cohort study—If applicable, explain how loss to follow-up was addressed         (d) Cohort study—If applicable, explain how matching of cases and controls was addressed       Cross-sectional study—If applicable, describe analytical methods taking account o sampling strategy         (e) Describe any sensitivity analyses       Describe any sensitivity analyses			is more than one group
Quantitative variables       11       Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why         Statistical methods       12       (a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions         (c) Explain how missing data were addressed       (d) Cohort study—If applicable, explain how loss to follow-up was addressed         (d) Cohort study—If applicable, explain how matching of cases and controls was addressed       Case-control study—If applicable, describe analytical methods taking account o sampling strategy         (e) Describe any sensitivity analyses       (e) Describe any sensitivity analyses	Bias	9	Describe any efforts to address potential sources of bias
describe which groupings were chosen and why         Statistical methods         12       (a) Describe all statistical methods, including those used to control for confounding         (b) Describe any methods used to examine subgroups and interactions         (c) Explain how missing data were addressed         (d) Cohort study—If applicable, explain how loss to follow-up was addressed         (a) Cohort study—If applicable, explain how matching of cases and controls was addressed         (c) Explain study—If applicable, describe analytical methods taking account o sampling strategy         (e) Describe any sensitivity analyses	Study size	10	Explain how the study size was arrived at
Statistical methods       12       (a) Describe all statistical methods, including those used to control for confounding         (b) Describe any methods used to examine subgroups and interactions       (c) Explain how missing data were addressed         (d) Cohort study—If applicable, explain how loss to follow-up was addressed         Case-control study—If applicable, explain how matching of cases and controls was addressed         Cross-sectional study—If applicable, describe analytical methods taking account o sampling strategy         (e) Describe any sensitivity analyses	Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable,
<ul> <li>(b) Describe any methods used to examine subgroups and interactions</li> <li>(c) Explain how missing data were addressed</li> <li>(d) Cohort study—If applicable, explain how loss to follow-up was addressed</li> <li>Case-control study—If applicable, explain how matching of cases and controls was addressed</li> <li>Cross-sectional study—If applicable, describe analytical methods taking account o sampling strategy</li> <li>(e) Describe any sensitivity analyses</li> </ul>			describe which groupings were chosen and why
<ul> <li>(c) Explain how missing data were addressed</li> <li>(d) Cohort study—If applicable, explain how loss to follow-up was addressed</li> <li>Case-control study—If applicable, explain how matching of cases and controls was addressed</li> <li>Cross-sectional study—If applicable, describe analytical methods taking account o sampling strategy</li> <li>(e) Describe any sensitivity analyses</li> </ul>	Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding
<ul> <li>(d) Cohort study—If applicable, explain how loss to follow-up was addressed</li> <li>Case-control study—If applicable, explain how matching of cases and controls was addressed</li> <li>Cross-sectional study—If applicable, describe analytical methods taking account o sampling strategy</li> <li>(e) Describe any sensitivity analyses</li> </ul>			(b) Describe any methods used to examine subgroups and interactions
Case-control study—If applicable, explain how matching of cases and controls was addressed         Cross-sectional study—If applicable, describe analytical methods taking account o sampling strategy         (e) Describe any sensitivity analyses			(c) Explain how missing data were addressed
Case-control study—If applicable, explain how matching of cases and controls was addressed         Cross-sectional study—If applicable, describe analytical methods taking account o sampling strategy         (e) Describe any sensitivity analyses			
addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account o sampling strategy ( <u>e</u> ) Describe any sensitivity analyses			
Cross-sectional study—If applicable, describe analytical methods taking account o         sampling strategy         (e) Describe any sensitivity analyses			
sampling strategy ( <u>e</u> ) Describe any sensitivity analyses			<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of
( <u>e</u> ) Describe any sensitivity analyses			
	Continued on next page		

Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed
		(b) Give reasons for non-participation at each stage
		(c) Consider use of a flow diagram
Descriptive	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information
data		on exposures and potential confounders
		(b) Indicate number of participants with missing data for each variable of interest
		(c) Cohort study—Summarise follow-up time (eg, average and total amount)
Outcome data	15*	Cohort study-Report numbers of outcome events or summary measures over time
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure
		Cross-sectional study-Report numbers of outcome events or summary measures
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their
		precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and
		why they were included
		(b) Report category boundaries when continuous variables were categorized
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion		
Key results	18	Summarise key results with reference to study objectives
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision.
		Discuss both direction and magnitude of any potential bias
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity
		of analyses, results from similar studies, and other relevant evidence
Generalisability	21	Discuss the generalisability (external validity) of the study results
Other informati	ion	
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable,
		for the original study on which the present article is based

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.




Figure 1 Overview of the five centres included in the study from the EPIC-InterAct study.

105x90mm (300 x 300 DPI)

**BMJ Open** 

Centre		Statistics fo	or each stud	y		н	lazard r	atio a	nd 959	% CI	
	Hazard ratio	Lower limit	Upper limit	p-value							
Bilthoven	1.87	1.13	3.09	0.015				-	-	-	
Cambridge	1.34	0.95	1.89	0.092				- †•			
Heidelberg	1.37	0.96	1.97	0.083				- H	╸┤		
Potsdam	1.32	0.96	1.81	0.085				- <b>⊢</b> ∎	-		
Umeå	1.03	0.77	1.37	0.852				-	•		
Pooled	1.29	1.09	1.53	0.003				<	>		
					0.1	0.2	0.5	1	2	5	10

p-value for heterogeneity 0.33, I2 index 13.3%

**Figure 2** Centre-specific and pooled hazard ratios of incident T2DM adjusted for the variables in the final model (age, sex, education, BMI, smoking, physical activity, alcohol consumption, energy intake and hypertension).

136x90mm (300 x 300 DPI)

# Appendix

 All questionnaires were standardized to fit the question (with four response alternatives):

How satisfied are you today with your health?

- 1 Excellent
- 2 Good
- 3 Moderate
- 4 Poor

Description of the original questions and how they were standardized:

Bilthoven 1993-94

# Question: What do you think about your health in general?

Response alternatives	Standardized
1 Excellent	1 Excellent
2 Good	2 Good
3 Reasonable	3 Moderate
4 Mediocre	4 Poor
5 Poor	4 Poor
9 More than 1 option indicated	Missing value

# Bilthoven 1995-97

Question: What do you think about your health in general?

Response alternatives	Standardized
1 Excellent	1 Excellent
2 Very good	2 Good
3 Good	2 Good
4 Reasonable	3 Moderate
5 Mediocre	4 Poor
9 More than 1 option indicated	Missing value

# Cambridge

Question: How would you rate your general health?

Response alternatives	Standardized
1 Excellent	1 Excellent
2 Good	2 Good
3 Moderate	3 Moderate
4 Poor	4 Poor

# Heidelberg

Question: On the whole, how satisfied are you today with your health?

Response alternatives	Standardized
1 Very satisfied	1 Excellent
2 More satisfied	2 Good
3 More dissatisfied	3 Moderate
4 Very dissatisfied	4 Poor
8 Do not know	Missing value

# Potsdam

# Question: On the whole, how satisfied are you today with your health?

Response alternatives	Standardized
1 Very satisfied	1 Excellent
2 More likely satisfied	2 Good
3 More likely dissatisfied	3 Moderate
4 Very dissatisfied	4 Poor
8 Do not know	Missing value

# Umeå

# Question: How do you judge that your state of health has been in the last year?

Response alternatives	Standardized	
1 Very well	1 Excellent	
2 Quiet well	2 Good	
3 Fairly well	3 Moderate	
4 Quiet bad	4 Poor	
5 Bad	4 Poor	
9 Inconsistent answer	Missing value	